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1 Abstract
2
3 Objective: Infection of human hepatocytes by the hepatitis C virus (HCV) is a multistep 
4 process involving both viral and host factors. microRNAs (miRNAs) are small non-coding 
5 RNAs that post-transcriptionally regulate gene expression. Given that miRNAs were 
6 indicated to regulate between 30% and 75% of all human genes, we aimed to investigate the 
7 functional and regulatory role of miRNAs for the HCV life cycle. 
8 Design: To systematically reveal human miRNAs affecting the HCV life cycle, we performed 
9 a two-step functional high-throughput miRNA mimic screen in Huh7.5.1 cells infected with 
10 recombinant cell culture-derived HCV. miRNA targeting was then assessed using a 
11 combination of computational and functional approaches. 
12 Results: We uncovered miR-501-3p and miR-619-3p as novel modulators of HCV 
13 assembly/release. We discovered that these miRNAs regulate O-linked N-acetylglucosamine 
14 (O-GlcNAc) transferase (OGT) protein expression and identified OGT and O-GlcNAcylation 
15 as regulators of HCV morphogenesis and infectivity. Furthermore, increased OGT 
16 expression in patient-derived liver tissue was associated with HCV-induced liver disease and 
17 cancer.
18 Conclusion: miR-501-3p and miR-619-3p and their target OGT are previously undiscovered 
19 regulatory host factors for HCV assembly and infectivity. In addition to its effect on HCV 
20 morphogenesis, OGT may play a role in HCV-induced liver disease and 
21 hepatocarcinogenesis. 
22
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4
Significance of this study
1
What is already known about this subject?
 To establish chronic infection, the hepatitis C virus (HCV) hijacks cellular factors 
including microRNAs (miRNAs), known to post-transcriptionally regulate gene 
expression. 
 miRNAs may positively or negatively modulate HCV infection either by directly 
targeting the viral genome or indirectly by regulating virus-associated cellular 
pathways[1, 2].
What are the new findings?
 A functional miRNA mimic screen uncovered miR-501-3p and miR-619-3p to 
enhance late steps of HCV infection.
 miR-501-3p regulates the expression of O-linked N-acetylglucosamine transferase 
(OGT) at the protein level.
 Silencing of OGT expression or inhibition of O-linked N-acetylglucosaminylation (O-
GlcNAcylation) leads to an increase in the infectivity and size of HCV particles.
 OGT expression increases in patient-derived liver tissue during liver disease 
progression and cancer.
How might it impact on clinical practice in the foreseeable future?
 As upregulation of OGT and increased O-GlcNAcylation of proteins have been 
associated with various forms of cancer, OGT may play a dual role in HCV 
morphogenesis as well as pathogenesis of HCV-induced liver disease and 
carcinogenesis.
2
3
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5
1 Introduction 
2 Chronic hepatitis C is a major cause of chronic liver disease and hepatocellular carcinoma 
3 (HCC). Since the approval of pan-genotypic direct-acting antivirals (DAAs), it is considered a 
4 curable disease in more than 90% of treated patients. Nonetheless, an estimated 71 million 
5 individuals are still infected by the hepatitis C virus (HCV) and several challenges remain; 
6 viral cure reduces but does not eliminate the HCC risk in patients with advanced fibrosis[3], 
7 the majority of infected patients has limited access to therapy and DAA failure/viral 
8 resistance has been reported in a subset of patients[4, 5]. To overcome these limitations, 
9 approaches to target host factors involved in HCV infection and pathogenesis are 
10 developed[6, 7]. Interestingly, defined host factors that contribute to the establishment of 
11 chronic HCV infection and represent potential antiviral targets, e.g. epidermal growth factor 
12 receptor[8], also play a role in liver disease pathogenesis and represent candidate targets for 
13 treatment of advanced liver disease and HCC prevention[9]. Thus, uncovering host factors 
14 usurped by HCV not only contributes to a better understanding of virus-host interactions 
15 underlying the HCV life cycle but also to the identification of potential targets for treatment of 
16 liver disease and prevention of HCC. 
17 The establishment of various models to study HCV infection has shed light on the 
18 molecular mechanisms that govern the HCV life cycle, which can be subdivided into early 
19 steps, including viral entry, translation and replication as well as late steps, including 
20 assembly and release of new virions. Each step of the HCV replication cycle relies on 
21 specific virus-host interactions that involve host proteins and microRNAs (miRNAs)[7], small 
22 non-coding RNAs that regulate gene expression at the post-transcriptional level. One miRNA 
23 can target numerous messenger RNAs (mRNAs) by base-pairing with a complementary site 
24 that is typically located within the 3′ untranslated region (3′UTR) of the mRNA. Accumulating 
25 evidence indicates that miRNAs participate to HCV replication by exerting pro- or antiviral 
26 effects. The breakthrough discovery of the direct targeting of HCV by miR-122, the most 
27 abundant miRNA in the liver, revealed the crucial role of this miRNA for HCV 
28 translation/replication that contributes to progression to chronic HCV infection[1, 10]. miR-
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6
1 122 antisense oligonucleotides were subsequently developed as host-targeting antivirals[11, 
2 12]. Other miRNAs can indirectly target HCV by regulating host factors that participate in 
3 antiviral responses and immune surveillance[2, 13, 14]. Since up to 60% of all human 
4 protein-coding genes were reported to be under miRNA-mediated regulation and miRNAs 
5 are involved in basically every biological process, we hypothesized that miRNAs provide a 
6 tool for loss-of-function approaches to uncover novel HCV host factors. We performed 
7 genome-wide high-throughput modulation of the human miRNome and analyzed their impact 
8 on HCV infection by combining computational and functional approaches. 
9
10 Material and methods
11 Cells, cell culture conditions, viruses, virus purification, infectivity assays, miRNAs, 
12 antagomiRs, siRNAs, antibodies, immunoblot, immunocapture, electron microscopy 
13 analysis of viral particles and gene expression analysis in liver tissue are described in 
14 the Supplementary information.
15
16 Functional miRNA/siRNA screens. Huh7.5.1 cells were transfected with the miRIDIAN 
17 human miRNA mimic library (mIRBase 19) comprising more than 2000 mature miRNAs or 28 
18 ON-TARGETplus smart pool siRNAs (20 nM, Dharmacon) using Interferin HTS (Polyplus) in 
19 a 96-well format[8]. After 48h, a viability test (Presto Blue, Thermo Scientific) was performed 
20 prior to a two-step infection assay[15, 16, 17]. During part 1 of the protocol, 50 µL of HCV cell 
21 culture-derived particles (HCVcc, JcR2a) were incubated with cells during 4h. The inoculum 
22 was removed and cells were incubated with 150 µl of medium for 48h. In part 2, supernatants 
23 from part 1 cells were transferred onto naïve Huh7.5.1 cells and part 1 cells were lysed to 
24 determine luciferase activity[17, 18]. After 72h, part 2 cells were lysed to determine luciferase 
25 activity[17]. siCD81 (20 nM), antagomiR-122 (100 nM) and siApoE (20 nM) were used as 
26 positive controls[17]. A non-targeting siRNA with no sequence complementarity to any 
27 human gene or homology to any human miRNA was used as negative control. 
28
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7
1 Inhibitor treatment. Four hours following HCV RNA electroporation[8], Huh7.5.1 cells were 
2 incubated with vehicle or inhibitors of OGT (peracetylated 5-thio-N-acetylglucosamine 
3 (Ac45S-GlcNAc)[19]) or OGA (Thiamet G (Sigma))[20]. After 96h, supernatants were 
4 transferred onto naïve Huh7.5.1 cells for 72h prior to determination of luciferase activity while 
5 electroporated cells were lysed to determine luciferase activity. 
6
7 Gene expression analyses. Total RNA was purified[17] and transcribed into cDNA using 
8 Maxima reverse transcriptase (Thermo Scientific). GAPDH and OGT mRNA was detected by 
9 real time qPCR using iTaq™ Universal Probes Supermix (Bio-Rad) and TaqMan Gene 
10 Expression Assay (Thermo Scientific). Relative OGT/GAPDH gene expression was 
11 calculated by the ΔΔCt method[21]. 
12
13 Dual luciferase reporter gene assay. The human OGT 3'UTR sequence was retrieved from 
14 NCBI (NM_181672.2) and Ensembl genome browser (ENST00000373719.3). A fragment of 
15 the OGT 3′UTR (positions 3380-3837, NM_181672.2) (Thermo Fisher Scientific GENEART) 
16 was cloned between the NotI and XhoI sites downstream of a Renilla luciferase cassette in a 
17 psiCHECK2 plasmid (Promega). A mutated version of this construct (9-bp substitution in the 
18 predicted miR-501-3p target site) was generated as described[22]. The functionality of the 
19 OGT 3′UTR was assessed as described[23]. The miRIDIAN mimic negative control 1 was 
20 used as control. Renilla and firefly luciferase activity was assessed 48h after transfection into 
21 HeLa cells using Dual-Luciferase Reporter assay (Promega).
22
23 Bioinformatic and statistical analysis. Data analysis and statistical treatment for the 
24 miRNA mimic screen were performed in R (www.r-project.org). Cell measurement data used 
25 in further analysis were cell viability and luciferase activity. In total 26 sets of plates 
26 (performed in triplicate) were tested. The presence of multiple wells with negative and 
27 positive controls on each plate allowed stepwise normalization intra- and inter-plate. First, 
28 intra-plate zonal bias was examined and a model of median effects across the entire screen 
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8
1 determined using the median-polish algorithm[24] and all plates corrected accordingly. Then 
2 the dataset was examined for outlier plates, i.e. plates where all individual measurements 
3 correlate very poorly with the other remaining replicates. Three and 9 plates were excluded 
4 for part 1 and part 2 of the screen, respectively, based on poor median correlation (r < 0.7) 
5 so that the remaining plates correlation improved substantially (> 40%). Next, the plates were 
6 normalized inter replicates using the particularly robust quantile-quantile approach[25]. 
7 Finally, the data were tested using a moderated t-test (empirical Bayes shrinkage, R-
8 package limma[26]) for the null-hypothesis of no change of a given miRNA compared to the 
9 negative control. The resulting p-values for independent testing of each miRNA where 
10 corrected for the multiple testing situation and expressed as local false discovery rate (lfdr, 
11 R-package fdrtool[27]). The testing was performed independently for part 1 and 2 of the 
12 screen and candidate miRNAs selected for each part. For data from part 1, a lfdr threshold of 
13 0.00027 was used. Data from part 2 were subject to increase inherent stochastic noise and 
14 for this reason the minimum acceptable relative risk of false positives was increased to 
15 0.1226 (i.e. maximum 15% risk for each of the retained hits). 
16 Other datasets were analyzed using the two-tailed Mann-Whitney test, Wilcoxon test, 
17 Spearman correlation or the two-tailed unpaired t-test for data with normal distribution as 
18 assessed by D'Agostino and Pearson omnibus and Shapiro-Wilk normality tests (GraphPad 
19 Prism v.6 package).
20
21
22 Results
23 Genome-wide identification of human miRNAs affecting the HCV life cycle. We 
24 performed a genome-wide screen in human hepatoma Huh7.5.1 cells using a genomic 
25 miRNA mimics library and a two-step infection assay[17] with a luciferase reporter virus 
26 (JcR2a), which allowed us to functionally assess the role of miRNAs during the early steps 
27 (part 1 - viral entry/translation/replication) and the late steps (part 2 - viral 
28 assembly/release/infectivity) of the HCV life cycle (Fig. 1A). Silencing of CD81 and ApoE, 
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9
1 two essential host factors required for HCV entry or assembly, respectively, was performed 
2 in parallel using small interfering RNA (siRNA) as controls. Silencing of CD81 resulted in a 
3 reduction of HCV infection in part 1 and consequently in part 2 of the screen since reduced 
4 viral entry in the first part of the assay leads to a reduced production of viral particles (Fig. 
5 1B)[17]. Silencing of ApoE resulted in a marked inhibition of HCV infection only in part 2 of 
6 the assay, consistent with the role of ApoE in HCV assembly (Fig. 1B)[17]. The screen 
7 identified 427 miRNAs (corresponding to about 16% of the library) that significantly 
8 modulated HCV infection (lfdr < threshold, Supplementary Table 1 and Fig. 1C): 186 miRNAs 
9 affected HCV infection in part 1, 309 miRNAs affected HCV infection in part 2, including 68 
10 hits in part 1 and part 2. The limited number of part 1 and 2 hits may be due to the fact that a 
11 single miRNA may modulate the expression of several proteins, which may have different 
12 roles in the viral life cycle. Most hits were observed to dampen HCV infection independently 
13 of any significant alteration of cell viability (data not shown). The 186 miRNAs modulating the 
14 early steps of HCV infection all decreased viral infection. Among the 309 miRNAs that had 
15 an impact in part 2, 11 miRNAs increased HCV infection by at least 3-fold while 298 miRNAs 
16 inhibited HCV infection by at least 2.7-fold. Hits from the screen included the let-7 family[2, 
17 28], miR-27a[29] and miR-29 family[30] that were already shown to inhibit HCV infection, as 
18 well as miR-21[31] and miR-146a-5p[17] that were shown to stimulate HCV infection thus 
19 supporting the relevance of our findings. Collectively, our screen identified a set of miRNAs 
20 whose overexpression overall impairs HCV infection by affecting viral 
21 entry/translation/replication and/or virion assembly/egress/infectivity. 
22
23 miR-619-3p, miR-501-3p and OGT play a role in late steps of the HCV life cycle. We 
24 focused our analysis on miRNAs that modulate late steps of the HCV life cycle, as the 
25 molecular mechanisms of HCV assembly/release remain only partially understood. Our 
26 screen identified 241 miRNAs that modulated late steps without affecting early steps of 
27 infection: 11 miRNAs increased HCV infection while 230 miRNAs decreased HCV infection. 
28 Among the miRNAs that increased HCV infection, miR-140-3p, miR-501-3p, miR-619-3p and 
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10
1 miR-4778-5p have not yet been associated with HCV. Since they enhanced HCV infection in 
2 part 2 without affecting part 1, these miRNAs may target host genes that control virus 
3 assembly/egress/infectivity. We first confirmed the effect of these miRNAs in independent 
4 experiments using the same protocol as for the screen. Overexpression of miR-619-3p or 
5 miR-501-3p consistently led to an increase in the infection of progeny virions (Fig. 1D) while 
6 infection was decreased with progeny virions from antagomiR-transfected cells 
7 (Supplementary Figure S1A). miR-619-3p or miR-501-3p were thus selected for further 
8 investigation. To study the molecular mechanisms by which these miRNAs affect HCV 
9 infection, we generated a list of predicted miRNA targets using DIANA, TargetScan Human 
10 v6.2 and miRDB databases, and selected candidate targets based on their expression in our 
11 Huh7.5.1 cells as assessed by microarray (data not shown). Ingenuity Pathway Analysis 
12 enabled us to refine the gene list by selecting 28 genes involved in the following functional 
13 networks or pathways that contribute to the HCV life cycle[32, 33, 34]: lipid metabolism and 
14 cholesterol biosynthesis, protein maturation and processing at the endoplasmic reticulum 
15 (ER), components of the endosomal sorting complex, adipocyte biogenesis, cellular 
16 morphology and cell inflammation (Table 1). 
17 To assess whether knock-down of these 28 candidate targets affects virus 
18 production, we performed a siRNA-based screen using siRNA pools exhibiting strong 
19 silencing without cytotoxicity (Fig. 2). Silencing of CD81 and antagomiR-122 served as 
20 controls for part 1; knock-down of ApoE served as control for part 2 (Fig. 2). Hits were 
21 defined as genes whose knock-down modulated HCV infection in at least one part of the 
22 screen with high significance (Fig. 2, p-value < 0.0001, Mann-Whitney U-test). HCV 
23 entry/translation/replication was significantly modulated by silencing of PPP3CA, CEBPA, 
24 MID1, WDFY3, DCX and SLC35D1. HCV assembly/egress/infectivity was significantly 
25 modulated by knock-down of PPP3CA, CSDE1, GAN, USP37, CEBPA, MID1, WDFY3, DCX, 
26 MAPK9, SLC35D1, DCC, RNF144A, PPP2R2C and OGT. Strikingly, only the silencing of 
27 OGT was associated with an enhancement of HCV assembly/release/infectivity (p-value = 
28 0.0002), while that of the other hits was associated with reduced HCV infection (Fig. 2). 
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11
1 These results indicate that the down-regulation of OGT phenocopies the effect of miR-501-
2 3p and miR-619-3p on HCV infection (Fig. 2) and suggest OGT as a novel player in the HCV 
3 life cycle. 
4
5 miR-501-3p post-transcriptionally regulates OGT expression. To study whether miR-501-
6 3p and miR-619-3p target OGT, we analyzed OGT RNA and protein levels in Huh7.5.1 cells 
7 following overexpression of miR-501-3p or miR-619-3p. While neither miRNA had an impact 
8 on OGT RNA levels (Fig. 3A), up-regulation of miR-501-3p significantly decreased OGT 
9 protein expression by ~65% (Fig. 3B, p-value < 0.05, t-test). miR-619-3p also decreased 
10 OGT expression but less robustly than miR-501-3p (Fig. 3B), prompting us to focus our 
11 investigation on miR-501-3p. To assess whether OGT is a functional target of miR-501-3p, 
12 we subcloned a fragment of the OGT mRNA 3′UTR that harbors the predicted miR-501-3p 
13 target site in the Renilla luciferase expression cassette (RLuc) of a dual luciferase reporter 
14 construct. Co-transfection of miR-501-3p mimic with the wild-type 3’UTR reporter (RLuc wt 
15 OGT 3’UTR) significantly decreased luciferase activity as compared to the empty vector (Fig. 
16 3C, p-value < 0.05, t-test). In contrast, the repression of luciferase expression was lost when 
17 the reporter with mutated miR-501-3p binding site (RLuc mt OGT 3’UTR) was used (Fig. 3C). 
18 These data are consistent in indicating that miR-501-3p mediates post-transcriptional 
19 regulation of OGT.
20
21 O-GlcNAcylation modulates HCVcc infectivity. To investigate whether OGT modulates 
22 HCV assembly and/or infectivity, we determined infectious virus titer (TCID50) and HCV RNA 
23 levels to calculate the specific infectivity of HCVcc particles generated in OGT-silenced 
24 Huh7.5.1 cells. Interestingly, OGT-silencing led to a significant increase in the TCID50 and 
25 the specific infectivity of HCVcc (Fig. 4A, p-value < 0.05, Mann-Whitney test). Noteworthy, 
26 the effect of OGT on HCVcc infectivity was genotype-independent as demonstrated by 
27 increased infectivity of HCVcc bearing the envelope glycoproteins of genotypes 1a, 1b and 
28 2a upon OGT-silencing (Fig. 4B). We next sought to investigate how OGT could modulate 
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12
1 HCVcc infectivity. OGT is the only enzyme that catalyzes the addition of N-
2 acetylglucosamine (O-GlcNAc) to serine and threonine residues of proteins. Moreover, OGT 
3 has a scaffold function and promotes binding of proteins in multiprotein complexes[35]. To 
4 assess whether the enzymatic activity of OGT modulates HCVcc infectivity, we used 
5 pharmacological inhibitors of OGT (Ac45S-GlcNAc) or O-GlcNAcase (OGA) (Thiamet G), the 
6 OGT counterpart that removes O-GlcNAc (Fig. 4C). Ac45S-GlcNAc led to a significant 
7 enhancement of HCVcc infectivity in a dose-dependent manner, while the opposite effect 
8 was observed with Thiamet G (Fig. 4D, p-value < 0.05, Mann-Whitney test). Collectively, 
9 these results demonstrate that O-GlcNAcylation modulates HCVcc infectivity. 
10
11 OGT-silencing affects HCVcc biophysical properties and size distribution. To further 
12 assess how OGT may impact HCVcc morphogenesis, we analyzed the structural and 
13 biophysical properties of HCVcc produced in siCtrl- and siOGT-transfected Huh7.5.1 cells 
14 following iodixanol gradient ultracentrifugation. Silencing of OGT led to the production of 
15 more infectious HCVcc with higher density (Fig. 5A-B) as well as higher ApoE concentrations 
16 (Fig. 5C) suggesting that OGT/O-GlcNAcylation affects the biophysical properties of HCVcc. 
17 No change in apoB concentrations were observed between HCVcc produced from siCtrl- or 
18 siOGT-transfected cells (Fig. 5D), in line with the model that HCV lipoviroparticles contain 
19 several exchangeable ApoE molecules and one non-exchangeable apoB[36]. We also 
20 visualized HCVcc by electron microscopy (EM) following anti-E2 antibody 
21 immunocapture[36] to assess whether OGT-silencing had an impact on HCVcc size. Particle 
22 size distribution was assessed from a series of randomly acquired electron micrographs. A 
23 shift towards bigger sizes was observed for sucrose-cushion purified HCVcc generated in 
24 OGT-silenced Huh7.5.1 cells as compared to control HCVcc (Fig. 6A-B). This shift was also 
25 observed in different fractions of iodixanol gradient-separated HCVcc (Fig. 6C-F) in line with 
26 the higher infectivity and ApoE concentrations of HCVcc generated in OGT-silenced 
27 Huh7.5.1 cells (Fig. 5A-C). These data suggest that OGT-silencing affects the lipidation of 
28 HCVcc.
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13
1 OGT expression increases in liver disease. Since silencing of OGT promotes HCV 
2 infectivity, we assessed whether HCV infection in turn had an effect on miR-501-3p and OGT 
3 expression. In Huh7.5.1 cells, HCV infection lead to small but significant increase of miR-
4 501-3p and decrease of OGT levels (Fig. 7A-B and Supplementary Fig. 1B; p-value < 0.05, 
5 Mann-Whitney test), which may promote viral infection given the pro- and antiviral roles of 
6 miR-501-3p and O-GlcNAcylation, respectively (Fig. 1C-D and 4D). In contrast, no significant 
7 difference of OGT expression was observed between the livers of HCV transgenic and wild-
8 type mice[37] (data not shown) suggesting that HCV proteins do not directly modulate OGT 
9 expression. In liver tissue from HCV-infected patients, HCV RNA levels were not correlated 
10 with OGT expression (Fig. 7C, Spearman correlation: 0.06004019, p-value = 0.7661) 
11 suggesting that in patients there is likely no direct effect of HCV on OGT expression. 
12 O-GlcNAcylation has been associated with a variety of cancers, including HCC 
13 recurrence linked to increased O-GlcNAcylation after liver transplantation[38]. We therefore 
14 investigated OGT expression in chronic liver disease and HCC. While there was a trend for 
15 increased OGT expression in liver tissue from HCV-infected patients with fibrosis and 
16 inflammation (Fig. 7D-E), OGT levels were markedly and significantly elevated in the tumor 
17 liver tissue of patients chronically infected with HCV or hepatitis B virus and patients with 
18 alcoholic liver disease or non-alcoholic fatty liver disease as compared to non-tumor tissue 
19 (Fig. 7F, p-value < 0.05, Wilcoxon test). These data suggest that OGT expression increases 
20 in HCC in an etiology-independent manner. Collectively, these results suggest that OGT 
21 expression is likely increased in HCV-induced liver disease and cancer through inflammation 
22 and fibrosis rather than by HCV itself. 
23
24
25 Discussion
26 By focusing on miRNAs affecting late steps of the viral life cycle, we uncovered that i) miR-
27 501-3p regulates the expression of OGT; ii) silencing of OGT expression or inhibition of its 
28 enzymatic activity increases the infectivity of HCV particles; and iii) OGT knock-down leads 
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14
1 to the release of bigger HCV particles. Our data suggest that O-GlcNAcylation affects HCV 
2 morphogenesis and infectivity. 
3 While we were characterizing the role of OGT/O-GlcNAcylation for HCV 
4 morphogenesis, Li and colleagues published their functional genomics study of HCV-miRNA 
5 interactions[2]. By conducting genome wide miRNA mimic and hairpin inhibitor screens, they 
6 identified a set of miRNAs exhibiting a pro- or antiviral effect on HCV. Characterization of the 
7 underlying molecular processes showed that miR-25, let-7 and miR-130 families restrict viral 
8 infection by decreasing the expression of cellular HCV co-factors[2]. Despite similarities in 
9 the cell type and HCV infection models used here and by Li and colleagues, our screen only 
10 displays a small overlap with their study (9% common miRNA hits). This is not surprising 
11 given the small overlap between previous siRNA screens to uncover HCV host factors[8, 15] 
12 and is likely due i) to the different sizes of miRNA mimic libraries as the library used here was 
13 more than 2-times larger than the one used by Li and co-workers, and ii) to the markedly 
14 distinct pipelines for hit selection that were used in the two studies. Nonetheless, both 
15 screens were consistent in confirming the proviral role of miR-146a-5p in promoting HCV 
16 assembly/egress that we previously reported[17] and the global multistep inhibitory effects of 
17 the let-7 family on HCV infection[28], further corroborating the involvement of these miRNAs 
18 in fine-tuning the HCV life cycle. Both studies also consistently indicated that miR-518a-5p, 
19 miR-517-3p, miR-185 and members of the miR-302 family inhibit early steps of HCV 
20 infection, while miR-586, miR-620 and members of the miR-200 family inhibit late steps of 
21 viral infection. Since none of these miRNAs except miR-185 has been previously associated 
22 with HCV infection[39], it might be interesting to further characterize the involvement of these 
23 miRNAs in HCV-host interactions. Interestingly, an overall proviral effect of miR-501-3p was 
24 also observed by Li and colleagues[2], however the mechanism of action was not studied. By 
25 characterizing the role of miR-501-3p in the HCV life cycle, we uncovered OGT as a miR-
26 501-3p target in liver-derived cells and showed for the first time a link between O-
27 GlcNAcylation and HCV infection. These results indicate that genome-wide miRNA functional 
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15
1 screens represent a powerful strategy to dissect the role of miRNAs in pathogen-host 
2 interactions. 
3 While N-glycosylation of HCV envelope glycoproteins plays an important role for 
4 escape from virus-neutralizing antibodies[40], so far no functional association between HCV 
5 and O-glycosylation has been reported. In contrast to N-linked glycosylation that consists of 
6 the attachment of a glycan to a nitrogen of an asparagine residue of proteins in the ER/Golgi 
7 prior to their trafficking to the plasma membrane and/or their secretion, the glycosylation of 
8 serine and threonine residues with O-GlcNAc is a post-translational modification (PTM) of 
9 intracellular proteins that are localized in the nucleus, cytoplasm or mitochondria. The O-
10 glycosylation/deglycosylatio  of proteins is catalyzed by a single pair of nucleo-cytoplasmic 
11 enzymes, OGT/OGA. O-GlcNAcylation is complementary to protein 
12 phosphorylation/dephosphorylation, another more broadly known abundant protein PTM that 
13 involves numerous kinases/phosphatases. OGT/OGA are often found in protein complexes 
14 that also include kinases/phosphatases and a protein can be either O-GlcNAcylated or 
15 phosphorylated on a same residue to fine-tune cellular signaling[41]. O-GlcNAcylation and 
16 phosphorylation on the same or neighboring serine or threonine residue is known as yin yang 
17 site[42]. 
18 O-GlcNAcylation plays a major role in the regulation of metabolic pathways in the 
19 liver, including insulin signaling, bile acid metabolism and lipogenesis[35]. The large number 
20 of OGT/OGA substrates and cellular pathways regulated by O-GlcNAcylation hampers a 
21 detailed characterization of the role of these proteins in HCV infection. Since i) HCV 
22 assembly takes place at ER-derived membranes, ii) OGT/OGA are not known to localize in 
23 the ER lumen, and iii) O-GlcNAcylation of extracellular proteins containing EGF-like domains 
24 is catalyzed by EGF domain-specific OGT (EOGT) in the ER lumen in an OGT-independent 
25 manner[43]), OGT/OGA most likely modulate HCV infection by post-translationally modifying 
26 one or several cellular factors required for HCV morphogenesis rather than by affecting viral 
27 proteins, although HCV glycoproteins contain putative O-GlcNAcylation sites as determined 
28 using OGlcNAcScan, OGTsite and YingOYang1.2 bioinformatics tools (data not shown). 
Page 16 of 84
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
16
1 Regarding HCV host factors that may be regulated by OGT/OGA, O-GlcNAcylation 
2 sites have been predicted in human CLDN1[44] and OCLN at serine sites that can also be 
3 phosphorylated and this has been suggested to potentially play a role for HCV entry[45]. 
4 However, in our experimental setting we did not observe a significant effect of OGT-silencing 
5 on the early steps of HCV infection, suggesting that O-GlcNAcylation of CLDN1 and/or 
6 OCLN likely does not play a major role in HCV infection. Other host factors important for the 
7 HCV life cycle are well-known O-GlcNAcylated proteins, as for example various nuclear pore 
8 complex proteins (Nups) including Nup98, Nup153 and Nup155 that are involved in HCV 
9 replication and assembly and/or may be associated with viral particles[46, 47, 48]. However, 
10 since depletion of Nups was reported to alter HCV replication and/or assembly but to have 
11 no impact on the specific infectivity of HCV particles[46] in contrast to the depletion of OGT 
12 as shown here, it is unlikely that a modulation of Nup O-GlcNAcylation accounts for the 
13 effects of OGT-silencing and/or OGT/OGA inhibitors on HCVcc infectivity observed in our 
14 study. This is in line with our observation that OGT knock-down had no effect on Dengue 
15 virus (DENV) replication and infectivity (unpublished observations KH, MZ and Evelyne 
16 Schaffer, IBMC, Strasbourg), although Nup98 had been suggested to potentially play a role 
17 for DENV infection[46]. These data suggest that OGT does not broadly modulate the 
18 infectivity of viruses of the Flaviviridae family. 
19 However, OGT and/or O-GlcNAcylation have been reported to play a role in the 
20 infection with other viruses[49, 50, 51]. Interestingly, while OGT expression modulates the 
21 levels of human papillomavirus 16 (HPV16) oncoproteins E6 and E7[52], E6 in turn can up-
22 regulate OGT to increase O-GlcNAcylation and the oncogene activities of HPV[53], 
23 suggesting that OGT/O-GlcNAcylation could play a role in virus-induced cancer. In cell 
24 culture, HCV infection appeared to be associated with a minor decrease in OGT expression 
25 in line with an antiviral role of O-GlcNAcylation. In contrast, an increased OGT expression 
26 was observed in HCC tissues of HCV-infected patients. Since OGT has been suggested to 
27 activate oncogenic signaling pathways in non-alcoholic steatohepatitis-related HCC[54] and 
28 O-GlcNAcylation has been associated with HCC recurrence linked to increased O-
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17
1 GlcNAcylation after liver transplantation[38], these data suggest that in addition to their effect 
2 on the HCV life cycle, OGT/O-GlcNAcylation may also play a role in HCV-induced 
3 hepatocarcinogenesis.
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1 Figure legends
2 Figure 1. High-throughput screen identifies human miRNAs that regulate the HCV life 
3 cycle. (A) Schematic outline of the miRNA mimic screen strategy. Huh7.5.1 cells were 
4 transfected with miRNA mimics or controls prior to infection with Renilla luciferase HCVcc 
5 (JcR2a) two days later (part 1). Cell supernatants of part 1 were used to inoculate naïve 
6 Huh7.5.1 cells (part 2). Cells from part 1 and part 2 were lysed at the end of each infection 
7 step (2 and 3 days post infection, respectively) to determine luciferase activity. (B) 
8 Modulation of HCV entry and replication (part 1) and/or assembly and infectivity (part 2) upon 
9 transfection of control non-targeting siRNA (siCtrl, negative control), siCD81 (inhibiting viral 
10 entry) or siApoE (inhibiting viral assembly). By inhibiting HCV entry, siCD81 impacts part 1 
11 as well as part 2. In contrast, by specifically impairing late steps of HCV replication cycle, 
12 siApoE inhibits HCV infection only in part 2. The box plots show the sample lower quartile 
13 (25th percentile; bottom of the box), the median (50th percentile; horizontal line in box) and 
14 the upper quartile (75th percentile; top of the box) of relative light units (RLU) in each lysate. 
15 The whiskers indicate s.d. Data are from three independent experiments. (C) Effects of 
16 miRNA overexpression on each part of the HCV life cycle. Data were tested using a 
17 moderated t-test (empirical Bayes shrinkage, R-package limma[26]) for the null-hypothesis of 
18 no change of a given miRNA compared to the negative control. The resulting p-values for 
19 independent testing of each miRNA where corrected for the multiple testing situation and 
20 expressed as local false discovery rate (lfdr, R-package fdrtool[27]). miRNAs having a 
21 significant effect on either part 1 or 2 of the screen are below the thresholds indicated by 
22 dashed lines (lfdr < 0.00027 or 0.1226, respectively). miRNAs that were previously reported 
23 to impact on HCV infection as well as miR-140-3p, miR-501-3p, miR-619-3p and miR-4778-
24 5p are highlighted in blue (Log2(FC) < 0) or red (Log2(FC) > 0). Data are from three 
25 independent experiments. (D) Effect of miR-140-3p, miR-501-3p, miR-619-3p and miR-4778-
26 5p on the HCV life cycle. Huh7.5.1 cells were transfected with siCtrl (Ctrl), miR-140-3p, miR-
27 501-3p, miR-619-3p or miR-4778-5p and infection experiments were carried out as described 
28 in A. HCV infection was determined as luciferase activity. Results represent mean 
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1 percentage ± s.d. from three independent experiments in triplicate. The dashed line indicates 
2 values from control-transfected cells set at 100%. Statistics: *, p-value < 0.05, Mann-Whitney 
3 test.
4
5 Figure 2. OGT is a novel host cell factor involved in the late steps of the HCV life cycle. 
6 Huh7.5.1 cells were transfected with a set of siRNAs against 28 predicted targets of miR-
7 501-3p and/or miR-619-3p, and infected with HCVcc JcR2A according to the two-step 
8 protocol depicted in Fig. 1A. siCD81, antagomiR-122 and siApoE were used as loss-of-
9 function controls to perturb HCV entry, translation/replication and assembly, respectively. 
10 miR-501-3p and miR-619-3p, which were ineffective in part 1 of the screen but enhanced 
11 HCV infection in part 2, were transfected in parallel. HCV infection was quantified as fold 
12 change of luciferase activity with respect to negative control (siCtrl). Results for different 
13 replicates are shown as individual points. For each gene, median fold change of luciferase 
14 activity ± s.d. is shown as black horizontal lines. The dashed line indicates a fold change of 
15 1. Data are from three independent experiments in triplicate. Results for miR-501-3p, miR-
16 619-3p and siOGT that increase HCV infection in part 2 are depicted in red. Results for 
17 siRNA targeting PPP3CA, CEBPA, MID1, WDFY3, DCX, SLC35D1, CSDE1, GAN, USP37, 
18 MAPK9, DCC, RNF144A, or PPP2R2C that significantly modulated HCV infection in part 1 
19 and/or part 2 but did not phenocopy the effect of miR-501-3p and miR-619-3p are depicted in 
20 blue.
21
22 Figure 3. miR-501-3p mediates post-transcriptional regulation of OGT by decreasing 
23 its expression at the protein level. Huh7.5.1 cells were transfected with siCtrl (Ctrl), a pool 
24 of siRNA against OGT, miR-501-3p or miR-619-3p. After 96h, RNA and proteins were 
25 purified, and OGT expression analyzed by RT-qPCR and Western blot. (A) Percentage of 
26 OGT mRNA expression in miRNA-transfected cells as compared to negative control. Results 
27 are presented as mean ± s.d. and are from three independent experiments in triplicate. The 
28 dashed line indicates values from control-transfected cells set at 100%. Statistics: *, p-value 
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1 < 0.05, t-test (B) OGT protein expression. Left: percentage of OGT protein expression in 
2 siRNA- or miRNA-transfected cells as assessed by quantification of Western blots. OGT 
3 levels were normalized to actin levels using ImageLab™ 5.2.1 software (BioRad). Results 
4 are presented as mean ± s.d. and are from three independent experiments. The dashed line 
5 indicates values from control-transfected cells set at 100%. Statistics: *, p-value < 0.05, t-
6 test. Right: representative Western blot analysis. (C) Analysis of miRNA targeting of OGT 
7 expression by dual luciferase reporter assay. Left: HeLa cells were co-transfected with a 
8 miR-501-3p mimic and a dual luciferase reporter plasmid containing either wild type miR-
9 501-3p (RLuc wt OGT 3’UTR) or mutated miR-501-3p binding site (RLuc mt OGT 3’UTR) to 
10 modulate RLuc expression. Co-transfection of the miR-501-3p mimic and empty RLuc vector 
11 was used as control. Data are expressed as mean percentage of Renilla luciferase activity ± 
12 s.d. normalized to firefly luciferase, and relative to co-transfection of the vectors with non-
13 targeting miRNA (miR-Ctrl). Results are from three independent experiments in triplicate. 
14 The dashed line indicates values from control-transfected cells set at 100%. Statistics: *, p-
15 value < 0.05, t-test. Right: Schematic representation of the used constructs. 
16
17 Figure 4. Silencing of OGT affects HCV morphogenesis and infectivity. (A) Analysis of 
18 HCV infectivity. Huh7.5.1 cells were transfected with siCtrl, a pool of siRNA against OGT or 
19 ApoE as a loss-of-function control to perturb HCV assembly, prior to infection with HCVcc 
20 (Jc1) two days later (entry and replication). Mock-transfected cells were used as control 
21 (Ctrl). After another 48h, intra- and extracellular HCVcc particles were used to infect naïve 
22 Huh7.5.1 cells (assembly and infectivity). Virus supernatants of Huh7.5.1 cells were assayed 
23 by (left) endpoint dilution assay (TCID50). Intra- and extracellular HCV RNA was purified and 
24 analyzed by RT-qPCR to calculate (right) the specific infectivity (TCID50/RNA). Data are 
25 expressed as mean percentage as compared to control ± s.d. Results are from four 
26 independent experiments in triplicate. The dashed line indicates values from control-
27 transfected cells set at 100%. Statistics: *, p-value < 0.05, Mann-Whitney test. (B) Genotype-
28 independent effect of OGT on HCV infection. Huh7.5.1 cells were transfected with siCtrl or 
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1 siOGT prior to infection with HCVcc JcR2a (genotype 2a), H77R2a (genotype 1a) or 
2 Con1R2a (genotype 1b). Experiments were carried out and analyzed as described in A. Data 
3 are expressed as mean percentage of Renilla luciferase activity as compared to control ± s.d. 
4 Results are from three independent experiments in quadruplicate. The dashed line indicates 
5 values from control-transfected cells set at 100%. Statistics: *, p-value < 0.05, Mann-Whitney 
6 test. (C) Activity of OGT/OGA inhibitors on O-GlcNAcylation. The activity of Ac45S-GlcNAc 
7 (OGT inhibitor) or Thiamet G (OGA inhibitor) on O-GlcNAcylation of proteins in Huh7.5.1 
8 cells was demonstrated by Western blot as described in Supplementary Methods. (D) Effect 
9 of O-GlcNAcylation on HCV infectivity. Huh7.5.1 cells were electroporated with HCVcc 
10 (JcR2a), prior to treatment with increasing concentrations of Ac45S-GlcNAc (OGT inhibitor, 
11 left) or Thiamet G (OGA inhibitor, right) 4h later. After 96h, supernatants were transferred 
12 onto naïve Huh7.5.1 cells and electroporated cells were lysed to determine luciferase 
13 activity. Luciferase activity in infected Huh7.5.1 cells was assessed 72h later. Data are 
14 expressed as mean percentage as compared to control ± s.d. Results are from three 
15 independent experiments in quadruplicate. The dashed line indicates values from vehicle-
16 treated cells set at 100%. Statistics: *, p-value < 0.05, Mann-Whitney test. 
17
18 Figure 5. Silencing of OGT modulates HCVcc biophysical properties. (A) Separation of 
19 HCVcc by iodixanol density gradient ultracentrifugation. HCVcc were produced in non-
20 targeting siRNA control- or siOGT-transfected Huh7.5.1 cells. After overlaying HCVcc 
21 (JcR2A) on a 4%-40% iodixanol step gradient and ultracentrifugation for 16h, fractions of 
22 HCV particles were used to infect naïve Huh7.5.1 cells in order to determine TCID50. HCV 
23 RNA of each fraction was purified and analyzed by RT-qPCR. Data are expressed as mean ± 
24 s.d. from three independent experiments. (B) Specific infectivity (TCID50/RNA) was 
25 calculated and the density was determined by weighting each fraction. Specific infectivity of 
26 each fraction is expressed as fold change as compared to the total infectivity of the control. 
27 Data are expressed as mean ± s.d. from three independent experiments. (C-D) ApoE and 
28 ApoB concentrations in the individual fractions were determined by ELISA. The dashed lines 
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1 indicate limits of quantification of the assays. Data are expressed as mean ± s.d. from three 
2 independent experiments. 
3
4 Figure 6. Silencing of OGT increases the size of HCVcc. (A) Representative pictures of 
5 HCV particles generated in Huh7.5.1 cells transfected with non-targeting siRNA (siCtrl) or 
6 siOGT. (B-F) Comparative analysis of particle size distribution for immunocapture (IC) from 
7 HCV particles produced in Huh7.5.1 cells transfected with siCtrl or siOGT prior to infection 
8 with HCVcc (JcR2a) following sucrose-cushion purification (B) or iodixanol gradient 
9 fractionation (C-F) of HCVcc. HCVcc were transferred via anti-E2 antibody AR3A on electron 
10 microscopy (EM) grids through IC. Particle size distribution was assessed from a series of 
11 randomly acquired electron micrographs with Image-J software (NIH). Results from one of 
12 three (A-B) or two (C-F) independent experiments are shown. Black lines: size distribution of 
13 immunocaptured HCVcc produced in siCtrl-transfected cells. Grey lines: size distribution of 
14 immunocaptured HCVcc produced in siOGT-transfected cells. 
15
16 Figure 7. OGT expression increases in HCC. (A-B) Huh7.5.1 cells were infected with HCV 
17 (JcR2a). After 72h, RNA and proteins were purified, and OGT expression analyzed by RT-
18 qPCR and Western blot. (A) Percentage of OGT mRNA expression relative to uninfected 
19 Huh7.5.1 cells (Ctrl). Results are presented as mean ± s.d. from three independent 
20 experiments in duplicate. The dashed line indicates values from uninfected Huh7.5.1 cells 
21 set at 100%. Statistics: *, p-value < 0.05, Mann-Whitney test. (B) OGT protein expression. 
22 Left: percentage of OGT protein expression relative to uninfected Huh7.5.1 cells (Ctrl) 
23 following quantification of Western blots as described in Supplementary Methods. Results 
24 are presented as mean ± s.d. from three independent experiments. The dashed line 
25 indicates values from uninfected Huh7.5.1 cells set at 100%. Statistics: *, p-value < 0.05, 
26 Mann-Whitney test. Right: representative Western blot analysis of OGT and actin. (C) OGT 
27 expression and viral load in liver tissue from 22 HCV-infected patients and 6 patients not 
28 infected with HCV described in[55]. Spearman correlation: rho = 0.06004019, p-value = 0.77. 
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1 (D-E) OGT expression in liver tissue from 22 HCV-infected patients and 6 patients not 
2 infected with HCV according to fibrosis (D) or activity (E) scores described in[55]. Wilcoxon 
3 test: F1 vs F0 p-value = 0,38; F2 vs F0 p-value = 0,18; F3 vs F0 p-value = 0,43; F4 vs F0 p-
4 value = 0,17; A1 vs A0 p-value = 0,28; A2 vs A0 p-value = 0,23; A3 vs A0 p-value = 0,09. (F) 
5 OGT expression in tumor (HCC) and non-tumor (Ctrl) liver tissue from 39 HCV-infected 
6 patients, 83 HBV-infected, 80 patients with alcoholic liver disease (ALD) and 13 patients with 
7 non-alcoholic liver disease (NAFLD) as described in Supplementary Methods. *, p-value < 
8 0.05, Wilcoxon test.
9
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1 Table 1. Computational analysis of miR-501-3p and miR-619-3p targets and pathway 
2 enrichment. 
miRNA ID Target gene symbol Pathway or network
miR-501-3p MEF2A; PPP3CA; PPP3CC Calcium signaling
HMGCS1 Cholesterol biosynthesis
AFF4; CHMP1B; CUX1; DCLK1; 
LMX1A; PTBP2; RBMS1; RC3H1; 
SCN2A; SEC63; ZFHX4
Inflammatory response, dermatological 
diseases and conditions, inflammatory 
disease
CDK6; CSDE1; GLI2; HOXD10; 
LSM5; MEF2A; MYCN; OGT; 
PPP2R2C; PPP2R5E; SEMA3C; 
TFDP2
Cellular development, nervous system 
development and function; organ 
morphology
CIT; COL10A1; FNBP1L; GAN; 
HERC1; KPNA4; NONO; SHPRH; 
STRN; TARDBP; UBE2H; USP37
Cell death and survival; cellular 
compromise; free radical scavenging
ATXN1; CBLL1; CEBPA; DCC; 
PEX5L; RCC2; RNF144A; ZC3H12C
Cell morphology, cellular assembly and 
organization; cellular function and 
maintenance
miR-619-3p RUNX1T1; SMAD3 Adipocyte biogenesis
FOXG1; GPBP1; MID1; MKL2; MSI1; 
PCBP2; WDFY3
Cell cycle; organismal injury and 
abnormalities; cancer
ACVR2B; DCX; ESRRG; MAPK9; 
OGT; PCBP1; PDE3B; SMAD3; 
SMARCC1; TGFB3; PAPOLA
Carbohydrate metabolism, energy 
production; small molecule biochemistry
RUNX1T1; SHANK2; SLC35D1 Gene expression, lipid metabolism, small 
molecule biochemistry
3
4
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1 Supplementary Information
2
3 A functional microRNA screen uncovers O-linked N-acetylglucosamine transferase as 
4 a host factor modulating hepatitis C virus morphogenesis
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22
23 Supplementary Material and methods
24 Cells and cell culture conditions. The source and culture conditions of Huh7.5.1 cells have 
25 been described[1]. HeLa cells were purchased from ATCC and cultured in Dulbecco´s 
26 modified Eagle medium (Gibco® DMEM GlutaMAX™, ThermoFisher Scientific) containing 1% 
27 sodium pyruvate as described for Huh7.5.1 cells[1]. 
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2
1 Viruses and infectivity assays. Cell culture-derived recombinant cell culture-derived 
2 hepatitis C virus (HCVcc) Jc1 (genotype 2a/2a chimera), H77R2a (genotype 1a/2a chimera 
3 engineered for Renilla luciferase expression), Con1R2a (genotype 1b/2b chimera engineered 
4 for Renilla luciferase expression), and JcR2a (genotype 2a/2a chimera engineered for Renilla 
5 luciferase expression) were generated in Huh7.5.1 cells as described[1, 2, 3, 4]. HCVcc 
6 infectivity was determined by calculating the 50% tissue culture infectious dose (TCID50) 
7 using anti-NS5A antibody as described[5, 6] or by assessing luciferase activity. HCVcc were 
8 used at 105-106 TCID50/mL throughout the study. HCV RNA was purified using a QIAmp viral 
9 RNA minikit (Qiagen) and analyzed by one-step RT-qPCR using a Sensi Fast NO ROX kit 
10 (Bioline) according to the manufacturer’s instructions. Standard curves were performed using 
11 10-fold dilution series of HCV RNA.
12
13 Purification of HCVcc particles using sucrose cushion or iodixanol density gradient. 
14 HCVcc (JcR2a) were concentrated 10-fold using a Vivaspin column (GE Healthcare). For 
15 sucrose cushion purification, HCVcc were purified by overlaying 3.5 mL of culture media on 
16 1.5 mL of 20% sucrose, and by ultracentrifuging samples for 4h at 40,000 rpm on a SW-55 
17 rotor (Beckman Coulter). Purified HCVcc were resuspended in 30 µL of PBS for analysis via 
18 immunocapture and electron microscopy. Density distributions of infectious HCVcc were 
19 determined by overlaying 0.5 mL culture media on a 5 mL, 4%-40% iodixanol step gradient, 
20 and ultracentrifuging samples for 16h at 40,000 rpm on a SW-55 rotor (Beckman Coulter): 625 
21 µl fractions were carefully harvested from the top of each tube, and density was determined 
22 by weighing. Infectivity of each fraction was quantified by TCID50 using anti-NS5A antibody 
23 as described[5, 6], while HCV RNA of fractions was purified and analyzed as described above. 
24 ApoB and ApoE concentrations of fractions were determined by enzyme-linked 
25 immunosorbent assay (Human Apolipoprotein B or E ELISAPRO kit, Mabtech) undiluted or in a 
26 1:50 dilution, respectively, according to the manufacturer’s instructions (Mabtech). 
27
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3
1 miRNA mimics and siRNAs. Non-targeting control miRNA, miR-501-3p mimic, miR-619-3p 
2 mimic, antagomiR-122, antagomiR-501-3p, non-targeting control antagomiR, non-targeting 
3 control siRNA, siRNAs targeting OGT, CD81 or apoliporotein E (ApoE) and a library of 28 
4 custom ON-TARGETplus smart pool siRNAs were purchased from Dharmacon (GE 
5 Healthcare).
6
7 miRNA expression analysis. Total RNA (100 ng) was purified from control or HCV-infected 
8 Huh7.5.1 cells using Tri reagent® (Thermo Scientific) and Direct-zol™ RNA purification kit 
9 (Zymo Research). Total RNA was first polyadenylated and reverse transcribed using a 
10 miScript II RT system (Qiagen) according to the manufacturer’s instructions. The obtained 
11 cDNA was subjected to RT-qPCR using miScript SYBR Green kit (Qiagen). Primers were the 
12 mature miRNA sequence for the forward primer (Thermo Scientific) and the universal miScript 
13 primer (Qiagen) for the reverse primer. Data were analyzed by the ΔΔCt method using small 
14 nucleolar RNA, C/D box 61 (SNORD61) as an endogenous reference and the non-infected 
15 samples as a calibrator[7].
16
17 Antibodies. Rabbit anti-OGT antibodies DM-17 and AL24 were purchased from Sigma or 
18 kindly provided by Dr. G. W. Hart and Dr. S. Hardivillé (Johns Hopkins University School of 
19 Medicine, Baltimore, MD)[8], respectively. Mouse anti--actin antibody was purchased from 
20 Abcam and mouse, rabbit or sheep HRP-conjugated secondary antibodies (A9044, A0545 
21 and A3415, respectively) were purchased from Sigma. Sheep anti-NS5A serum for 
22 determination of TCID50 was a kind gift from M. Harris[9]. Human anti-E2 (AR3A) antibody[10] 
23 for electron microscopy analysis was kindly provided by Mansun Law (SCRIPPS, California, 
24 USA). 
25
26 Western blotting. OGT and actin protein expression in human cells was assessed by 
27 Western blot as described[8] with some modifications. Briefly, cells were lysed in lysis buffer 
28 no. 6 (R&D Systems) according to the manufacturer's instructions. Equal amounts of protein 
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4
1 (40 µg) were size-separated through a Mini PROTEAN® TGX Stain-Free™ gel electrophoresis 
2 (Bio-Rad) and transferred to PVDF membranes (Bio-Rad). Immunoblots were performed 
3 using rabbit anti-OGT (1:2000) and mouse anti--actin (1:1000) antibodies[8, 11]. Antigen-
4 antibody complexes were detected by incubating the membrane with the appropriate HRP-
5 conjugated secondary antibodies (1:5000; 1:10,000) and imaged by enhanced 
6 chemiluminescence with a ChemiDoc MP imager (Bio-Rad). Quantification of protein 
7 expression was performed using ImageLab™ 5.2.1 software (BioRad). For analysis of OGT 
8 and GAPDH expression in liver tissue from HCV transgenic (FL-N/35) or wild-type mice[12], 
9 crude protein extracts were prepared by homogenization of frozen mouse livers (50–100 µg) 
10 in tissue lysis buffer from the Ambion PARIS RNA (Thermo Scientific) and protein isolation kit, 
11 supplemented with protease inhibitors (cOmpleteTM EDTA-free protease inhibitor mixture, 
12 Sigma-Aldrich) and phosphatase inhibitors (PhosSTOPTM, Sigma-Aldrich), using a tissue 
13 homogenizer (MP Fast Prep24, MP Biomedicals, Santa Ana, CA) and MP Lysing Matrix A 
14 tubes. Proteins were quantified using the BCA assay (Thermo Fisher Scientific). Western 
15 blotting was performed as described above.
16
17 Immunocapture and electron microscopy analysis of viral particles. Sucrose-cushion 
18 purified or iodixanol gradient fractionated HCVcc (JcR2a) produced in cells transfected with a 
19 non-targeting siRNA control or a pool of siRNA against OGT were transferred via anti-E2 
20 antibody AR3A on electron microscopy (EM) grids through immunocapture (IC) as 
21 described[13]. Particles were stained with uranyl acetate dihydrate and observed in a JEOL 
22 1230 electron microscope. Series of electron micrographs were acquired at random from IC 
23 EM grids. The images were then analyzed with Image-J software, to determine the particle 
24 size distribution.
25
26 Gene expression analysis in patient-derived liver tissue. For OGT expression analysis in 
27 patient’s samples, raw data were retrieved from the Gene Expression Omnibus (GSE84346) 
28 and re-analyzed by quality-trimming (cutadapt) and mapping (HISAT2) to human genome 
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5
1 assembly hg19. Reads mapping to Gencode v.19 genes were counted using htseq-count and 
2 normalized applying DESeq2. Activity and fibrosis scores as well as viral load were taken from 
3 the supplemental data published in[14]. To analyze OGT expression in liver tissue of chronic 
4 hepatitis B or C patients, FPKM values and clinical data were retrieved from The Cancer 
5 Genome Atlas (TCGA, https://www.cancer.gov/about-
6 nci/organization/ccg/research/structural-genomics/tcga). This data set includes samples from 
7 39 HCV-infected patients, 83 hepatitis B virus (HBV)-infected, 80 patients with alcoholic liver 
8 disease (ALD) and 13 patients with non-alcoholic fatty liver disease (NAFLD). 
9
10 Supplementary References
11 1 Zhong J, Gastaminza P, Cheng G, et al. Robust hepatitis C virus infection in vitro. Proc 
12 Natl Acad Sci U S A 2005;102:9294-9.
13 2 Reiss S, Rebhan I, Backes P, et al. Recruitment and activation of a lipid kinase by 
14 hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. 
15 Cell Host Microbe 2011;9:32-45.
16 3 Da Costa D, Turek M, Felmlee DJ, et al. Reconstitution of the entire hepatitis C virus 
17 life cycle in non-hepatic cells. J Virol 2012;86:11919-25.
18 4 Fauvelle C, Felmlee DJ, Crouchet E, et al. Apolipoprotein E Mediates Evasion From 
19 Hepatitis C Virus Neutralizing Antibodies. Gastroenterology 2016;150:206-17 e4.
20 5 Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in 
21 cell culture. Science 2005;309:623-6.
22 6 Bandiera S, Pernot S, El Saghire H, et al. Hepatitis C Virus-Induced Upregulation of 
23 MicroRNA miR-146a-5p in Hepatocytes Promotes Viral Infection and Deregulates Metabolic 
24 Pathways Associated with Liver Disease Pathogenesis. J Virol 2016;90:6387-400.
25 7 Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) 
26 method. Nat Protoc 2008;3:1101-8.
27 8 Iyer SP, Akimoto Y, Hart GW. Identification and cloning of a novel family of coiled-coil 
28 domain proteins that interact with O-GlcNAc transferase. J Biol Chem 2003;278:5399-409.
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6
1 9 Macdonald A, Crowder K, Street A, et al. The hepatitis C virus non-structural NS5A 
2 protein inhibits activating protein-1 function by perturbing ras-ERK pathway signaling. J Biol 
3 Chem 2003;278:17775-84.
4 10 Giang E, Dorner M, Prentoe JC, et al. Human broadly neutralizing antibodies to the 
5 envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A 2012;109:6205-
6 10.
7 11 Verrier ER, Colpitts CC, Bach C, et al. A targeted functional RNA interference screen 
8 uncovers glypican 5 as an entry factor for hepatitis B and D viruses. Hepatology 2016;63:35-
9 48.
10 12 Lerat H, Honda M, Beard MR, et al. Steatosis and liver cancer in transgenic mice 
11 expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 
12 2002;122:352-65.
13 13 Piver E, Boyer A, Gaillard J, et al. Ultrastructural organisation of HCV from the 
14 bloodstream of infected patients revealed by electron microscopy after specific 
15 immunocapture. Gut 2017;66:1487-95.
16 14 Boldanova T, Suslov A, Heim MH, et al. Transcriptional response to hepatitis C virus 
17 infection and interferon-alpha treatment in the human liver. EMBO Mol Med 2017;9:816-34.
18
19 Supplementary figure legends
20 Figure S1. (A) Effect of miR-501-3p inhibition on HCV infectivity. Huh7.5.1 cells were 
21 transfected with control antagomiR (Ctrl), antagomiR-122 as loss-of-function control to perturb 
22 HCV replication and antagomiR-501-3p, prior to infection with HCVcc (JcR2a) according to 
23 the two-step protocol depicted in Fig. 1A. After 48h, supernatants were transferred onto naive 
24 Huh7.5.1 cells. After 72h, Renilla Luciferase activity of infected Huh7.5.1 cells was 
25 determined. Data are expressed as mean percentage as compared to Ctrl ± s.d. Results are 
26 from four independent experiments in quadruplicate. The dashed line indicates values from 
27 vehicle-treated cells set at 100%. Statistics: *, p-value < 0.05, Mann-Whitney test. (B) miR-
28 501-3p expression upon HCV infection. Huh7.5.1 cells were infected with HCVcc (JcR2a). 
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7
1 After 72h, RNA was purified and miR-501-3p expression analyzed by RT-qPCR. Percentage 
2 of miR-501-3p expression relative to uninfected Huh7.5.1 cells (Ctrl). Results are presented 
3 as mean ± s.d. from three independent experiments in duplicate. The dashed line indicates 
4 values from uninfected Huh7.5.1 cells set at 100%. Statistics: *, p-value < 0.05, Mann-Whitney 
5 test.
6
7 Supplementary Table 1. A genome-wide miRNA mimic screen identifies cellular 
8 miRNAs modulating HCV infection. Log2(FC), lfdr and effect on HCV infection in part 1 and 
9 part 2 of the screen are shown for the individual miRNAs of the miRNA mimic library. In red: 
10 proviral effect, in blue: antiviral effect. FC: fold change, lfdr: local false discovery rate
Page 45 of 84
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Log2(FC) lfdr Effect on HCV Log2(FC) lfdr Effect on HCV
hsa-let-7a MIMAT0000062 C-300473-05 UGAGGUAGUAGGUUGUAUAGUU -1.70171935969617 3.9917e-05 TRUE -3.28400225976063 0.0018396 TRUE
hsa-let-7b MIMAT0000063 C-300476-05 UGAGGUAGUAGGUUGUGUGGUU -1.74684091191792 8.3715e-05 TRUE -3.61453853652595 0.009387 TRUE
hsa-let-7d MIMAT0000065 C-300478-07 AGAGGUAGUAGGUUGCAUAGUU -1.53075932976348 0.00023985 TRUE -2.74632167025162 0.057617 TRUE
hsa-let-7e MIMAT0000066 C-300479-05 UGAGGUAGGAGGUUGUAUAGUU -1.30271875995011 0.0014577 FALSE -1.90993819018051 0.081661 TRUE
hsa-let-7f MIMAT0000067 C-300480-05 UGAGGUAGUAGAUUGUAUAGUU -2.22178435619614 6.7884e-06 TRUE -3.76872186786763 0.014453 TRUE
hsa-let-7g MIMAT0000414 C-300583-05 UGAGGUAGUAGUUUGUACAGUU -1.91269526615093 6.7884e-06 TRUE -2.71878759599202 0.057617 TRUE
hsa-miR-101 MIMAT0000099 C-300518-07 UACAGUACUGUGAUAACUGAA -0.886376348041933 0.0030028 FALSE -1.9796810124946 0.11887 TRUE
hsa-miR-103-as MIMAT0007402 C-301453-00 UCAUAGCCCUGUACAAUGCUGCU -1.11208100417218 0.0074787 FALSE -2.91287954813545 0.057617 TRUE
hsa-miR-106a* MIMAT0004517 C-301159-01 CUGCAAUGUAAGCACUUCUUAC -1.32520114049511 3.9917e-05 TRUE -2.3773966141336 0.11887 TRUE
hsa-miR-1178 MIMAT0005823 C-301319-00 UUGCUCACUGUUCUUCCCUAG -1.22556728667978 0.00061109 FALSE -2.3126959903038 0.08542 TRUE
hsa-miR-1178-5p MIMAT0022940 C-301922-00 CAGGGUCAGCUGAGCAUG -1.16672245017752 0.00026644 TRUE -0.780775920183507 0.72813 FALSE
hsa-miR-1185 MIMAT0005798 C-301317-00 AGAGGAUACCCUUUGUAUGUU -1.2315368528283 8.3715e-05 TRUE -0.721316088104541 0.76975 FALSE
hsa-miR-1200 MIMAT0005863 C-301326-00 CUCCUGAGCCAUUCUGAGCCUC -1.24866404694154 0.00054279 FALSE -2.09711908610931 0.08542 TRUE
hsa-miR-1205 MIMAT0005869 C-301331-00 UCUGCAGGGUUUGCUUUGAG -0.801511472736558 0.0053924 FALSE -3.77846481724539 0.0018396 TRUE
hsa-miR-1207-3p MIMAT0005872 C-301334-00 UCAGCUGGCCCUCAUUUC -1.10040811819955 0.00013963 TRUE -1.69117584901668 0.26604 FALSE
hsa-miR-122 MIMAT0000421 C-300591-05 UGGAGUGUGACAAUGGUGUUUG -0.70369537171691 0.040577 FALSE -3.13425305602985 0.028781 TRUE
hsa-miR-122* MIMAT0004590 C-301046-01 AACGCCAUUAUCACACUAAAUA -0.557131436052541 0.037103 FALSE -1.83404561163316 0.11887 TRUE
hsa-miR-1226 MIMAT0005577 C-301284-01 UCACCAGCCCUGUGUUCCCUAG -0.741744822716559 0.0099219 FALSE -1.89688153334356 0.11887 TRUE
hsa-miR-1228* MIMAT0005582 C-301287-01 GUGGGCGGGGGCAGGUGUGUG -0.947568053691086 0.0049772 FALSE -2.29154418859234 0.11887 TRUE
hsa-miR-1237-5p MIMAT0022946 C-302618-00 CGGGGGCGGGGCCGAAGCGCG -0.956259568604456 0.021994 FALSE -2.34546898601693 0.057617 TRUE
hsa-miR-1244 MIMAT0005896 C-301865-00 AAGUAGUUGGUUUGUAUGAGAUGGUU -1.17945761818024 6.1693e-05 TRUE -0.989861012597079 0.5811 FALSE
hsa-miR-1245b-3p MIMAT0019951 C-302405-00 UCAGAUGAUCUAAAGGCCUAUA -0.414846848981959 0.32544 FALSE -2.27819747964432 0.081661 TRUE
hsa-miR-1255b-2-3p MIMAT0022725 C-301882-00 AACCACUUUCUUUGCUCAUCCA -0.427268737714942 0.061384 FALSE -2.58892190360625 0.023579 TRUE
hsa-miR-1258 MIMAT0005909 C-301384-00 AGUUAGGAUUAGGUCGUGGAA -1.57210875214914 1.5894e-05 TRUE -1.63979276673705 0.36109 FALSE
hsa-miR-125b-2* MIMAT0004603 C-301061-01 UCACAAGUCAGGCUCUUGGGAC -0.858902068537019 0.0052694 FALSE -1.87406855538924 0.11887 TRUE
hsa-miR-1260b MIMAT0015041 C-301716-00 AUCCCACCACUGCCACCAU -0.476317862532308 0.10991 FALSE 2.46099391534969 0.057617 TRUE
hsa-miR-1270 MIMAT0005924 C-301867-00 CUGGAGAUAUGGAAGAGCUGUGU -1.23553336541613 3.9917e-05 TRUE -2.24160380684469 0.11887 TRUE
hsa-miR-1277 MIMAT0005933 C-301411-00 UACGUAGAUAUAUAUGUAUUUU -0.745198002045239 0.0074787 FALSE -3.58615793633136 0.014453 TRUE
hsa-miR-1278 MIMAT0005936 C-301417-00 UAGUACUGUGCAUAUCAUCUAU -0.494528345361641 0.089234 FALSE 1.60846287059147 0.12226 TRUE
hsa-miR-1283 MIMAT0005799 C-301315-00 UCUACAAAGGAAAGCGCUUUCU -0.538161112092319 0.061384 FALSE -2.67520055202511 0.08542 TRUE
hsa-miR-1284 MIMAT0005941 C-301423-00 UCUAUACAGACCCUGGCUUUUC -0.412436737654723 0.099257 FALSE -2.28002191497783 0.11527 TRUE
hsa-miR-1287 MIMAT0005878 C-301341-00 UGCUGGAUCAGUGGUUCGAGUC -1.20683701032783 0.00023985 TRUE -1.98393331688063 0.08542 TRUE
hsa-miR-1288 MIMAT0005942 C-301424-00 UGGACUGCCCUGAUCUGGAGA -0.704889827052788 0.0021076 FALSE -2.89790974514386 0.057617 TRUE
hsa-miR-129-3p MIMAT0004605 C-301063-01 AAGCCCUUACCCCAAAAAGCAU -0.999602920325089 0.0021076 FALSE -1.88681635888787 0.11887 TRUE
hsa-miR-1291 MIMAT0005881 C-301345-00 UGGCCCUGACUGAAGACCAGCAGU -1.21284220826454 0.00061109 FALSE -2.02374608043906 0.11887 TRUE
hsa-miR-1293 MIMAT0005883 C-301347-00 UGGGUGGUCUGGAGAUUUGUGC -1.39687224389743 0.00026644 TRUE -2.31295737423138 0.057617 TRUE
hsa-miR-1294 MIMAT0005884 C-301348-00 UGUGAGGUUGGCAUUGUUGUCU -1.44051810095446 8.3715e-05 TRUE -1.95652126826796 0.057617 TRUE
hsa-miR-1295 MIMAT0005885 C-301349-00 UUAGGCCGCAGAUCUGGGUGA -1.2640855905457 0.00087976 FALSE -2.34227893604624 0.11887 TRUE
hsa-miR-1295b-5p MIMAT0022293 C-302563-00 CACCCAGAUCUGCGGCCUAAU -0.454374224389677 0.17522 FALSE -2.73444344828677 0.023579 TRUE
hsa-miR-1298 MIMAT0005800 C-301318-00 UUCAUUCGGCUGUCCAGAUGUA -0.26688230187125 0.32544 FALSE -2.44553337713544 0.11887 TRUE
hsa-miR-1302 MIMAT0005890 C-301869-00 UUGGGACAUACUUAUGCUAAA -1.35138412635794 3.6715e-05 TRUE -2.60359528922327 0.057617 TRUE
hsa-miR-1302 MIMAT0005890 C-301354-00 UUGGGACAUACUUAUGCUAAA -1.11168868347783 0.00013793 TRUE -1.29913904583381 0.51048 FALSE
hsa-miR-1307 MIMAT0005951 C-301434-00 ACUCGGCGUGGCGUCGGUCGUG -1.12000717587297 0.00054279 FALSE -2.10295176202445 0.057617 TRUE
hsa-miR-1307-5p MIMAT0022727 C-301875-00 UCGACCGGACCUCGACCGGCU -0.803481003211417 0.0030028 FALSE -1.76491161834359 0.11887 TRUE
hsa-miR-1322 MIMAT0005953 C-301436-00 GAUGAUGCUGCUGAUGCUG -1.23817643374983 6.1693e-05 TRUE -1.29920754317295 0.46329 FALSE
hsa-miR-1323 MIMAT0005795 C-301311-00 UCAAAACUGAGGGGCAUUUUCU -0.756897047236657 0.096607 FALSE -2.43084213259459 0.11887 TRUE
hsa-miR-135b* MIMAT0004698 C-301200-01 AUGUAGGGCUAAAAGCCAUGGG -1.49530939618539 0.0018747 FALSE -2.98188718020305 0.050122 TRUE
hsa-miR-139-3p MIMAT0004552 C-301036-03 UGGAGACGCGGCCCUGUUGGAGU -1.02065377094153 0.00079918 FALSE -2.77458369079406 0.019699 TRUE
hsa-miR-140-3p MIMAT0004597 C-301055-01 UACCACAGGGUAGAACCACGG -0.172675601522775 1 FALSE 2.56894688372309 0.11887 TRUE
hsa-miR-142-3p MIMAT0000434 C-300610-03 UGUAGUGUUUCCUACUUUAUGGA -1.00474764620935 0.00023985 TRUE -1.7577126946261 0.22566 FALSE
hsa-miR-146a MIMAT0000449 C-300630-03 UGAGAACUGAAUUCCAUGGGUU 0.279820319960687 0.17522 FALSE 1.66479155066337 0.11887 TRUE
hsa-miR-150* MIMAT0004610 C-301067-01 CUGGUACAGGCCUGGGGGACAG -1.46501526099695 0.00023985 TRUE -1.19620229448666 0.40677 FALSE
hsa-miR-151b MIMAT0010214 C-301973-00 UCGAGGAGCUCACAGUCU -1.03668648961171 3.9917e-05 TRUE -2.8985532020104 0.057617 TRUE
hsa-miR-182 MIMAT0000259 C-300557-07 UUUGGCAAUGGUAGAACUCACACU -0.581360116993454 0.03164 FALSE -1.81305061189634 0.11887 TRUE
hsa-miR-184 MIMAT0000454 C-300635-03 UGGACGGAGAACUGAUAAGGGU -1.31700777618768 3.9917e-05 TRUE -1.52851322717993 0.36109 FALSE
hsa-miR-185 MIMAT0000455 C-300636-07 UGGAGAGAAAGGCAGUUCCUGA -1.59673044023595 0.00013963 TRUE -1.74454670174015 0.1633 FALSE
hsa-miR-18b* MIMAT0004751 C-301187-01 UGCCCUAAAUGCCCCUUCUGGC -0.825568919117559 0.0027607 FALSE -2.30862554668178 0.023579 TRUE
hsa-miR-1909 MIMAT0007883 C-301456-00 CGCAGGGGCCGGGUGCUCACCG -0.511863313449074 0.17522 FALSE 2.49877552994666 0.11887 TRUE
hsa-miR-1915* MIMAT0007891 C-301466-00 ACCUUGCCUUGCUGCCCGGGCC -1.71935071114424 8.3715e-05 TRUE -1.13532112712663 0.46329 FALSE
hsa-miR-196b* MIMAT0009201 C-301305-00 UCGACAGCACGACACUGCCUUC -0.949306838412525 0.00054279 FALSE -3.1358874675771 0.023579 TRUE
hsa-miR-19b MIMAT0000074 C-300489-03 UGUGCAAAUCCAUGCAAAACUGA -1.01461439258753 0.00013793 TRUE -2.75192926226938 0.014453 TRUE
hsa-miR-19b-1* MIMAT0004491 C-301021-01 AGUUUUGCAGGUUUGCAUCCAGC -1.68388148726454 0.0030028 FALSE -2.85695043305243 0.014453 TRUE
hsa-miR-19b-2* MIMAT0004492 C-301139-01 AGUUUUGCAGGUUUGCAUUUCA -0.594068837054281 0.037103 FALSE -2.06967686748099 0.11887 TRUE
hsa-miR-200b* MIMAT0004571 C-301144-01 CAUCUUACUGGGCAGCAUUGGA -1.05721574165849 0.0074787 FALSE -4.59657299807562 0.0018396 TRUE
hsa-miR-203b-5p MIMAT0019813 C-302277-00 UAGUGGUCCUAAACAUUUCACA -1.0335612225008 0.00016067 TRUE -2.13526669981558 0.08542 TRUE
hsa-miR-208a MIMAT0000241 C-300537-03 AUAAGACGAGCAAAAAGCUUGU -0.823665097293502 0.0030028 FALSE -1.54639877799123 0.11887 TRUE
hsa-miR-21 MIMAT0000076 C-300492-03 UAGCUUAUCAGACUGAUGUUGA -0.768228630205262 0.096607 FALSE 3.29607415881261 0.057617 TRUE
hsa-miR-211-3p MIMAT0022694 C-301905-00 GCAGGGACAGCAAAGGGGUGC -0.812107428438748 0.0027607 FALSE -2.21028883028492 0.08542 TRUE
hsa-miR-2114 MIMAT0011156 C-301489-00 UAGUCCCUUCCUUGAAGCGGUC -0.958796902783202 0.00016326 TRUE -1.5768286317563 0.26604 FALSE
hsa-miR-2114* MIMAT0011157 C-301490-00 CGAGCCUCAAGCAAGGGACUU -1.02419077915881 0.00013793 TRUE -2.57866858794879 0.057617 TRUE
hsa-miR-2117 MIMAT0011162 C-301496-00 UGUUCUCUUUGCCAAGGACAG -0.806177347742896 0.00054279 FALSE -2.55943646917884 0.057617 TRUE
hsa-miR-216a-3p MIMAT0022844 C-301886-00 UCACAGUGGUCUCUGGGAUUAU -1.47806207137632 8.3715e-05 TRUE -1.62257411616963 0.1633 FALSE
hsa-miR-22 MIMAT0000077 C-300493-03 AAGCUGCCAGUUGAAGAACUGU -1.14812626998085 0.00054279 FALSE -2.8254651928315 0.009387 TRUE
hsa-miR-220b MI0005529 C-301218-01 CCACCACCGUGUCUGACACUU -1.10856445415353 0.12653 FALSE -2.50799687656707 0.11887 TRUE
hsa-miR-221* MIMAT0004568 C-301163-01 ACCUGGCAUACAAUGUAGAUUU -1.0647285020049 0.00016067 TRUE 0.493351763855846 0.86349 FALSE
hsa-miR-223* MIMAT0004570 C-301197-01 CGUGUAUUUGACAAGCUGAGUU -0.596047980424722 0.0074787 FALSE -2.64001675119474 0.057617 TRUE
hsa-miR-2276 MIMAT0011775 C-301481-00 UCUGCAAGUGUCAGAGGCGAGG -1.23563628890583 3.9917e-05 TRUE -0.719842576977581 0.76975 FALSE
hsa-miR-2277-3p MIMAT0011777 C-301482-00 UGACAGCGCCCUGCCUGGCUC -1.22725149342576 3.9917e-05 TRUE -2.2780178572373 0.11887 TRUE
hsa-miR-23a* MIMAT0004496 C-301025-01 GGGGUUCCUGGGGAUGGGAUUU -0.773715976814457 0.0018747 FALSE -2.22574058493535 0.11887 TRUE
hsa-miR-25* MIMAT0004498 C-301183-01 AGGCGGAGACUUGGGCAAUUG -1.14410824968417 0.0018747 FALSE -2.13159960818718 0.057617 TRUE
hsa-miR-2681-3p MIMAT0013516 C-301978-00 UAUCAUGGAGUUGGUAAAGCAC -0.84154241088718 0.00023985 TRUE -0.564927523090931 0.86349 FALSE
hsa-miR-2681-5p MIMAT0013515 C-301977-00 GUUUUACCACCUCCAGGAGACU -1.20496402288836 3.6715e-05 TRUE -2.40988448605506 0.057617 TRUE
hsa-miR-2682-3p MIMAT0013518 C-301980-00 CGCCUCUUCAGCGCUGUCUUCC -0.908772237664288 0.00013793 TRUE -1.43184476418853 0.29187 FALSE
hsa-miR-2682-5p MIMAT0013517 C-301979-00 CAGGCAGUGACUGUUCAGACGUC -1.24830345350196 1.5894e-05 TRUE -2.80779774369284 0.014453 TRUE
hsa-miR-26b MIMAT0000083 C-300501-07 UUCAAGUAAUUCAGGAUAGGU -0.405072630482104 0.12653 FALSE -2.50877510131769 0.081661 TRUE
hsa-miR-27a MIMAT0000084 C-300502-03 UUCACAGUGGCUAAGUUCCGC -1.32790971119818 3.9917e-05 TRUE -1.95676458087438 0.1633 FALSE
hsa-miR-27a* MIMAT0004501 C-301028-01 AGGGCUUAGCUGCUUGUGAGCA -0.887009503478049 0.0052694 FALSE -3.44308089121935 0.028781 TRUE
hsa-miR-27b* MIMAT0004588 C-301154-01 AGAGCUUAGCUGAUUGGUGAAC -1.00848877755825 0.0014577 FALSE -2.34115081043794 0.050122 TRUE
hsa-miR-28-5p MIMAT0000085 C-300503-05 AAGGAGCUCACAGUCUAUUGAG -0.358344656239635 0.17522 FALSE -1.5918060993224 0.11887 TRUE
hsa-miR-2861 MIMAT0013802 C-301642-00 GGGGCCUGGCGGUGGGCGG -0.615484847088555 0.0046172 FALSE -2.44784331747309 0.081661 TRUE
hsa-miR-2964a-3p MIMAT0019748 C-302218-00 AGAAUUGCGUUUGGACAAUCAGU -1.13977573653624 6.1693e-05 TRUE -0.558827938583115 0.76975 FALSE
hsa-miR-298 MIMAT0004901 C-301212-01 AGCAGAAGCAGGGAGGUUCUCCCA -0.456122353506126 0.54004 FALSE -2.83068032162142 0.11887 TRUE
hsa-miR-299-5p MIMAT0002890 C-300854-03 UGGUUUACCGUCCCACAUACAU -1.25864926851518 0.00023985 TRUE -0.317867194423722 1 FALSE
hsa-miR-29a* MIMAT0004503 C-301178-01 ACUGAUUUCUUUUGGUGUUCAG -1.35357089379682 0.0021076 FALSE -2.75349311494331 0.057617 TRUE
hsa-miR-29b-1* MIMAT0004514 C-301150-01 GCUGGUUUCAUAUGGUGGUUUAGA -0.970652939446982 0.015067 FALSE -2.38342736203068 0.11887 TRUE
hsa-miR-301b MIMAT0004958 C-301252-01 CAGUGCAAUGAUAUUGUCAAAGC -0.837318501823261 0.0014577 FALSE -2.28547978225747 0.11887 TRUE
hsa-miR-302b* MIMAT0000714 C-300668-07 ACUUUAACAUGGAAGUGCUUUC -0.550910910384927 0.037103 FALSE -1.76045353694163 0.12226 TRUE
hsa-miR-302f MIMAT0005932 C-301410-00 UAAUUGCUUCCAUGUUU -1.5960005623826 1.5894e-05 TRUE -3.17802223827817 0.014453 TRUE
hsa-miR-30b MIMAT0000420 C-300590-03 UGUAAACAUCCUACACUCAGCU -0.759206041294187 0.0018747 FALSE -2.5817157170778 0.057617 TRUE
hsa-miR-30c-1* MIMAT0004674 C-301199-01 CUGGGAGAGGGUUGUUUACUCC -1.43787786865803 8.3715e-05 TRUE 0.291968781990601 1 FALSE
hsa-miR-30c-2* MIMAT0004550 C-301034-01 CUGGGAGAAGGCUGUUUACUCU -1.18964958597662 8.3715e-05 TRUE -0.203715081689554 1 FALSE
hsa-miR-30d MIMAT0000245 C-300543-03 UGUAAACAUCCCCGACUGGAAG -0.469794284958227 0.061384 FALSE -2.24325814749711 0.08542 TRUE
hsa-miR-3115 MIMAT0014977 C-301644-00 AUAUGGGUUUACUAGUUGGU -0.595634685516391 0.0052694 FALSE -2.22531374934429 0.11887 TRUE
hsa-miR-3116 MIMAT0014978 C-301645-00 UGCCUGGAACAUAGUAGGGACU -1.61818516940984 6.7884e-06 TRUE -1.27627977004857 0.51048 FALSE
hsa-miR-3117 MIMAT0014979 C-301647-00 AUAGGACUCAUAUAGUGCCAG -1.07944692693698 6.1693e-05 TRUE 0.0583708702116637 1 FALSE
hsa-miR-3119 MIMAT0014981 C-301651-00 UGGCUUUUAACUUUGAUGGC -0.77136494055742 0.00087976 FALSE -2.20041353445194 0.11887 TRUE
hsa-miR-3121 MIMAT0014983 C-301654-00 UAAAUAGAGUAGGCAAAGGACA -0.550473953423974 0.0074787 FALSE -2.06892978205979 0.11887 TRUE
hsa-miR-3124 MIMAT0014986 C-301657-00 UUCGCGGGCGAAGGCAAAGUC -1.13549064733399 3.9917e-05 TRUE -0.910461837996433 0.5811 FALSE
hsa-miR-3126-5p MIMAT0014989 C-301661-00 UGAGGGACAGAUGCCAGAAGCA -1.43373948465677 1.5894e-05 TRUE -0.744651597941774 0.76975 FALSE
hsa-miR-3127 MIMAT0014990 C-301662-00 AUCAGGGCUUGUGGAAUGGGAAG -0.992180086498039 0.00013793 TRUE -1.20167440176899 0.51048 FALSE
hsa-miR-3130-3p MIMAT0014994 C-301665-00 GCUGCACCGGAGACUGGGUAA -0.645251817092445 0.0021076 FALSE -3.33421355039417 0.023579 TRUE
hsa-miR-3130-5p MIMAT0014995 C-301666-00 UACCCAGUCUCCGGUGCAGCC -1.12058237373742 6.1693e-05 TRUE -2.44166606880781 0.11887 TRUE
hsa-miR-3131 MIMAT0014996 C-301669-00 UCGAGGACUGGUGGAAGGGCCUU -1.10475333868087 6.1693e-05 TRUE -0.776623344642163 0.76864 FALSE
hsa-miR-3132 MIMAT0014997 C-301670-00 UGGGUAGAGAAGGAGCUCAGAGGA -1.0649683988313 8.3715e-05 TRUE -2.09592053963675 0.11887 TRUE
hsa-miR-3136 MIMAT0015003 C-301676-00 CUGACUGAAUAGGUAGGGUCAUU -0.837973854149906 0.00054279 FALSE -2.76623087444917 0.057617 TRUE
hsa-miR-3137 MIMAT0015005 C-301678-00 UCUGUAGCCUGGGAGCAAUGGGGU -1.05179643968079 8.3715e-05 TRUE -1.1088570611196 0.51579 FALSE
hsa-miR-3138 MIMAT0015006 C-301679-00 UGUGGACAGUGAGGUAGAGGGAGU -1.09246960431895 6.1693e-05 TRUE -1.78790357269758 0.22566 FALSE
hsa-miR-3139 MIMAT0015007 C-301680-00 UAGGAGCUCAACAGAUGCCUGUU -1.37716815069908 1.5894e-05 TRUE -1.31106163706907 0.46329 FALSE
hsa-miR-3140 MIMAT0015008 C-301681-00 AGCUUUUGGGAAUUCAGGUAGU -1.58079760272847 6.7884e-06 TRUE -3.18144016432131 0.014453 TRUE
hsa-miR-3142 MIMAT0015011 C-301684-00 AAGGCCUUUCUGAACCUUCAGA -0.977053358967313 0.00013963 TRUE -1.89446739540295 0.1633 FALSE
hsa-miR-3144-5p MIMAT0015014 C-301687-00 AGGGGACCAAAGAGAUAUAUAG -1.13947775501217 3.9917e-05 TRUE -0.414321660104908 1 FALSE
hsa-miR-3147 MIMAT0015019 C-301692-00 GGUUGGGCAGUGAGGAGGGUGUGA -0.942186557775687 0.00023985 TRUE -0.157149408887514 1 FALSE
hsa-miR-3148 MIMAT0015021 C-301694-00 UGGAAAAAACUGGUGUGUGCUU -1.14553360648851 3.9917e-05 TRUE -1.08300314433575 0.51579 FALSE
hsa-miR-3150 MIMAT0015023 C-301696-00 CUGGGGAGAUCCUCGAGGUUGG -1.4167699283789 1.5894e-05 TRUE -0.986527775853387 0.5811 FALSE
hsa-miR-3150b-5p MIMAT0019226 C-301961-00 CAACCUCGAGGAUCUCCCCAGC -1.04471163915449 3.9917e-05 TRUE -2.12053729635218 0.08542 TRUE
hsa-miR-3151 MIMAT0015024 C-301697-00 GGUGGGGCAAUGGGAUCAGGU -1.02537680303558 0.00013793 TRUE -1.56671822128811 0.26604 FALSE
hsa-miR-3152 MIMAT0015025 C-301698-00 UGUGUUAGAAUAGGGGCAAUAA -1.13601969432149 6.1693e-05 TRUE -2.17593163296179 0.11887 TRUE
hsa-miR-3157 MIMAT0015031 C-301704-00 UUCAGCCAGGCUAGUGCAGUCU -1.81838879899633 0.00023985 TRUE -0.798984655509925 0.76975 FALSE
hsa-miR-3180 MIMAT0018178 C-301583-00 UGGGGCGGAGCUUCCGGAG -1.37633415637047 0.00013793 TRUE -1.9747378577519 0.050122 TRUE
hsa-miR-3186-5p MIMAT0015067 C-301749-00 CAGGCGUCUGUCUACGUGGCUU -0.536494894531891 0.061384 FALSE -2.19613374331388 0.11887 TRUE
hsa-miR-3190-5p MIMAT0015073 C-301756-02 UCUGGCCAGCUACGUCCCCA -1.56898213610615 3.9917e-05 TRUE -3.02592555730969 0.014453 TRUE
hsa-miR-3191-5p MIMAT0022732 C-302750-00 CUCUCUGGCCGUCUACCUUCCA -0.896644736818671 0.01741 FALSE -2.93191055011036 0.057617 TRUE
hsa-miR-32* MIMAT0004505 C-301181-01 CAAUUUAGUGUGUGUGAUAUUU -0.561723514860645 0.37761 FALSE -2.47247129599692 0.11887 TRUE
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hsa-miR-323-5p MIMAT0004696 C-301085-01 AGGUGGUCCGUGGCGCGUUCGC -0.997451491983143 0.0049772 FALSE -2.55198466781697 0.014453 TRUE
hsa-miR-323b-5p MIMAT0001630 C-301724-00 AGGUUGUCCGUGGUGAGUUCGCA -0.870040751918234 0.00054279 FALSE -3.51049237466915 0.014453 TRUE
hsa-miR-324-3p MIMAT0000762 C-300705-05 ACUGCCCCAGGUGCUGCUGG -0.930125097729152 0.0021076 FALSE -2.18712046531723 0.081661 TRUE
hsa-miR-328 MIMAT0000752 C-300695-03 CUGGCCCUCUCUGCCCUUCCGU -1.1639709975505 8.3715e-05 TRUE -1.57395137899233 0.26604 FALSE
hsa-miR-339-3p MIMAT0004702 C-301185-01 UGAGCGCCUCGACGACAGAGCCG -0.424124048504717 0.061384 FALSE -2.06515171637643 0.08542 TRUE
hsa-miR-342-5p MIMAT0004694 C-301083-01 AGGGGUGCUAUCUGUGAUUGA -1.66163157467999 0.00016326 TRUE -2.01939161434937 0.12226 TRUE
hsa-miR-345-3p MIMAT0022698 C-301887-00 GCCCUGAACGAGGGGUCUGGAG -0.839605975652715 0.0021076 FALSE -2.80466918793858 0.023579 TRUE
hsa-miR-346 MIMAT0000773 C-300712-03 UGUCUGCCCGCAUGCCUGCCUCU -1.22592404544756 0.00023985 TRUE -1.35203588028221 0.20114 FALSE
hsa-miR-34a* MIMAT0004557 C-301145-01 CAAUCAGCAAGUAUACUGCCCU -1.27197605437233 6.1693e-05 TRUE -0.378051811558674 1 FALSE
hsa-miR-3529-5p MIMAT0019828 C-302292-00 AGGUAGACUGGGAUUUGUUGUU -0.674576387471472 0.034257 FALSE -1.99747275957492 0.11887 TRUE
hsa-miR-3612 MIMAT0017989 C-301505-00 AGGAGGCAUCUUGAGAAAUGGA -1.26286494709099 0.00026644 TRUE -1.44238772362423 0.51048 FALSE
hsa-miR-3616-3p MIMAT0017996 C-301512-00 CGAGGGCAUUUCAUGAUGCAGGC -1.10327166715049 0.00054279 FALSE -1.69108153949499 0.11887 TRUE
hsa-miR-3619-3p MIMAT0019219 C-301952-00 GGGACCAUCCUGCCUGCUGUGG -0.361591800679582 0.037103 FALSE -2.1201206119135 0.11887 TRUE
hsa-miR-3620-5p MIMAT0022967 C-302619-00 GUGGGCUGGGCUGGGCUGGGCC -0.963210303847923 0.01741 FALSE -2.95077111022971 0.014453 TRUE
hsa-miR-3622b-5p MIMAT0018005 C-301522-00 AGGCAUGGGAGGUCAGGUGA -1.03124833680421 0.00087976 FALSE -1.86140566900932 0.08542 TRUE
hsa-miR-365 MIMAT0000710 C-300666-03 UAAUGCCCCUAAAAAUCCUUAU -1.07713706038737 0.03164 FALSE -2.565586989697 0.12226 TRUE
hsa-miR-3654 MIMAT0018074 C-301532-00 GACUGGACAAGCUGAGGAA -0.394926641879625 0.096607 FALSE -1.99274206927806 0.057617 TRUE
hsa-miR-365b-5p MIMAT0022833 C-301900-00 AGGGACUUUCAGGGGCAGCUGU -1.17934943470937 0.00026644 TRUE -1.48034463468101 0.22566 FALSE
hsa-miR-3666 MIMAT0018088 C-301546-00 CAGUGCAAGUGUAGAUGCCGA -0.8322031427779 0.0027607 FALSE -2.76031104596189 0.009387 TRUE
hsa-miR-3667-3p MIMAT0018090 C-301547-00 ACCUUCCUCUCCAUGGGUCUUU -1.53737106921222 6.1693e-05 TRUE -0.189890808664278 1 FALSE
hsa-miR-3674 MIMAT0018097 C-301555-00 AUUGUAGAACCUAAGAUUGGCC -0.686422173208126 0.0099219 FALSE -1.66427885423157 0.08542 TRUE
hsa-miR-3675-5p MIMAT0018098 C-301557-00 UAUGGGGCUUCUGUAGAGAUUUC -0.704414688397948 0.0074787 FALSE -1.47755963621301 0.11887 TRUE
hsa-miR-3676-5p MIMAT0022734 C-301954-00 AGGAGAUCCUGGGUU -0.876412168433536 0.00016326 TRUE -2.81631813362903 0.028781 TRUE
hsa-miR-3680 MIMAT0018106 C-301565-00 GACUCACUCACAGGAUUGUGCA -0.710055072199479 0.0074787 FALSE -1.48818626629073 0.11887 TRUE
hsa-miR-3680* MIMAT0018107 C-301564-00 UUUUGCAUGACCCUGGGAGUAGG -0.68553099516054 0.0099219 FALSE -1.8440688012842 0.057617 TRUE
hsa-miR-3681 MIMAT0018108 C-301566-00 UAGUGGAUGAUGCACUCUGUGC -1.41416859913926 0.00013793 TRUE -1.60964747472672 0.1633 FALSE
hsa-miR-3681* MIMAT0018109 C-301567-00 ACACAGUGCUUCAUCCACUACU -1.39472879333958 0.00013793 TRUE -1.15667754722324 0.26604 FALSE
hsa-miR-3682 MIMAT0018110 C-301568-00 UGAUGAUACAGGUGGAGGUAG -1.46673360047121 8.3715e-05 TRUE -0.643125216570606 0.72813 FALSE
hsa-miR-3682-5p MIMAT0019222 C-301956-00 CUACUUCUACCUGUGUUAUCAU -1.23125674549655 1.5894e-05 TRUE -2.81908923583428 0.023579 TRUE
hsa-miR-3684 MIMAT0018112 C-301570-00 UUAGACCUAGUACACGUCCUU -0.580463595828849 0.021994 FALSE -1.45573759159026 0.11887 TRUE
hsa-miR-3688 MIMAT0018116 C-301574-00 UAUGGAAAGACUUUGCCACUCU -0.832441806479729 0.0027607 FALSE -2.02033498247755 0.057617 TRUE
hsa-miR-3688-5p MIMAT0019223 C-301957-00 AGUGGCAAAGUCUUUCCAUAU -0.588424467468018 0.0030028 FALSE -2.09619814608759 0.11887 TRUE
hsa-miR-3689b* MIMAT0018181 C-301587-00 CUGGGAGGUGUGAUAUUGUGGU -1.45567876271802 9.6971e-05 TRUE -1.73246672882077 0.081661 TRUE
hsa-miR-3691 MIMAT0018120 C-301578-00 AGUGGAUGAUGGAGACUCGGUAC -1.18761474653793 0.00054279 FALSE -1.75547134579776 0.057617 TRUE
hsa-miR-3691-3p MIMAT0019224 C-301958-00 ACCAAGUCUGCGUCAUCCUCUC -0.810629756562153 0.00026644 TRUE -1.96328717500158 0.11887 TRUE
hsa-miR-374a MIMAT0000727 C-300681-05 UUAUAAUACAACCUGAUAAGUG -0.718874319759212 0.0021076 FALSE -2.60836689817691 0.081661 TRUE
hsa-miR-374c MIMAT0018443 C-301630-00 AUAAUACAACCUGCUAAGUGCU -0.337432743025632 0.32544 FALSE -1.98175619738517 0.11887 TRUE
hsa-miR-374c-3p MIMAT0022735 C-301969-00 CACUUAGCAGGUUGUAUUAUAU -0.646260597978354 0.0018747 FALSE -2.63477891317834 0.028781 TRUE
hsa-miR-376c MIMAT0000720 C-300674-05 AACAUAGAGGAAAUUCCACGU -0.624380737173221 0.0053924 FALSE -2.68639877338995 0.057617 TRUE
hsa-miR-378b MIMAT0014999 C-301672-00 ACUGGACUUGGAGGCAGAA -0.950272981825821 0.00016326 TRUE -0.901403427172712 0.72813 FALSE
hsa-miR-378g MIMAT0018937 C-302000-00 ACUGGGCUUGGAGUCAGAAG -0.836483927856313 0.00023985 TRUE -1.88595985918819 0.11887 TRUE
hsa-miR-380* MIMAT0000734 C-300688-03 UGGUUGACCAUAGAACAUGCGC -1.15838836623363 0.0018747 FALSE -2.13916483631805 0.12226 TRUE
hsa-miR-381-5p MIMAT0022862 C-301920-00 AGCGAGGUUGCCCUUUGUAUAU -0.569567310635211 0.021994 FALSE -2.14982823754668 0.08542 TRUE
hsa-miR-383 MIMAT0000738 C-300692-03 AGAUCAGAAGGUGAUUGUGGCU -0.925079491666264 0.0052694 FALSE -2.8317437192294 0.050122 TRUE
hsa-miR-3907 MIMAT0018179 C-301585-00 AGGUGCUCCAGGCUGGCUCACA -1.38465900005315 0.00013793 TRUE -0.257773760992354 1 FALSE
hsa-miR-3910 MIMAT0018184 C-301590-00 AAAGGCAUAAAACCAAGACA -0.501095287980396 0.037103 FALSE -1.43931285152292 0.11887 TRUE
hsa-miR-3913-3p MIMAT0019225 C-301959-00 AGACAUCAAGAUCAGUCCCAAA -2.00645940017379 2.9753e-06 TRUE -3.02362886477847 0.014453 TRUE
hsa-miR-3918 MIMAT0018192 C-301600-00 ACAGGGCCGCAGAUGGAGACU -0.975422481909615 0.015067 FALSE -2.44273172350024 0.081661 TRUE
hsa-miR-3922-5p MIMAT0019227 C-301962-00 UCAAGGCCAGAGGUCCCACAGCA -1.00561107859174 6.1693e-05 TRUE -1.71505157929257 0.1633 FALSE
hsa-miR-3935 MIMAT0018350 C-301618-00 UGUAGAUACGAGCACCAGCCAC -0.43578505271152 0.17522 FALSE -2.47251139472301 0.057617 TRUE
hsa-miR-3972 MIMAT0019357 C-302158-00 CUGCCAGCCCCGUUCCAGGGCA -1.16965458786124 0.00023985 TRUE -1.70649157359084 0.40677 FALSE
hsa-miR-3975 MIMAT0019360 C-302161-00 UGAGGCUAAUGCACUACUUCAC -1.37543164339877 8.3715e-05 TRUE -1.26480301471027 0.51579 FALSE
hsa-miR-425* MIMAT0001343 C-300718-07 AUCGGGAAUGUCGUGUCCGCCC -0.937175749542432 0.00054279 FALSE -3.15498966014918 0.028781 TRUE
hsa-miR-4253 MIMAT0016882 C-301816-00 AGGGCAUGUCCAGGGGGU -1.35070000422013 0.00016326 TRUE -2.47892017845828 0.11887 TRUE
hsa-miR-4290 MIMAT0016921 C-301856-00 UGCCCUCCUUUCUUCCCUC -1.2579851622971 0.00026644 TRUE -0.780428141336904 0.86349 FALSE
hsa-miR-4306 MIMAT0016858 C-301792-00 UGGAGAGAAAGGCAGUA -1.10160128889539 0.0046172 FALSE -2.08580333486915 0.11887 TRUE
hsa-miR-4312 MIMAT0016864 C-301798-00 GGCCUUGUUCCUGUCCCCA -0.866321092589685 0.0030028 FALSE -2.71345507691741 0.11887 TRUE
hsa-miR-4314 MIMAT0016868 C-301802-00 CUCUGGGAAAUGGGACAG -1.5364651282067 8.3715e-05 TRUE -1.29173007577176 0.5811 FALSE
hsa-miR-4417 MIMAT0018929 C-301991-00 GGUGGGCUUCCCGGAGGG -0.611560680456615 0.0021076 FALSE -2.09593331520836 0.11887 TRUE
hsa-miR-4418 MIMAT0018930 C-301992-00 CACUGCAGGACUCAGCAG -0.946166316606651 0.00013793 TRUE -1.12537501301133 0.46329 FALSE
hsa-miR-4419a MIMAT0018931 C-301993-00 UGAGGGAGGAGACUGCA -1.57297371821019 6.7884e-06 TRUE -1.73343971226014 0.1633 FALSE
hsa-miR-4420 MIMAT0018933 C-301995-00 GUCACUGAUGUCUGUAGCUGAG -0.924563865566564 0.00013963 TRUE -0.533919074584704 0.86349 FALSE
hsa-miR-4422 MIMAT0018935 C-301997-00 AAAAGCAUCAGGAAGUACCCA -0.890570506779186 0.00023985 TRUE -0.609244483333412 0.86349 FALSE
hsa-miR-4423-3p MIMAT0018936 C-301999-00 AUAGGCACCAAAAAGCAACAA -0.908201173118296 0.00013793 TRUE -0.922983857808818 0.5811 FALSE
hsa-miR-4423-5p MIMAT0019232 C-301998-00 AGUUGCCUUUUUGUUCCCAUGC -0.973577427508824 8.3715e-05 TRUE -1.75215013385816 0.1633 FALSE
hsa-miR-4425 MIMAT0018940 C-302003-00 UGUUGGGAUUCAGCAGGACCAU -2.09487999782656 6.0932e-07 TRUE -4.02209575968718 0.0018396 TRUE
hsa-miR-4426 MIMAT0018941 C-302004-00 GAAGAUGGACGUACUUU -1.51937100953274 6.7884e-06 TRUE -1.79705743821345 0.12226 TRUE
hsa-miR-4427 MIMAT0018942 C-302005-00 UCUGAAUAGAGUCUGAAGAGU -0.853522749406319 0.00023985 TRUE -1.87772807758284 0.1633 FALSE
hsa-miR-4428 MIMAT0018943 C-302006-00 CAAGGAGACGGGAACAUGGAGC -1.00869386291556 6.1693e-05 TRUE -2.00933698314586 0.12226 TRUE
hsa-miR-4430 MIMAT0018945 C-302008-00 AGGCUGGAGUGAGCGGAG -0.738546756609574 0.00054279 FALSE -2.96189732903016 0.014453 TRUE
hsa-miR-4431 MIMAT0018947 C-302010-00 GCGACUCUGAAAACUAGAAGGU -0.605956299781477 0.0021076 FALSE -1.84934532554394 0.11887 TRUE
hsa-miR-4432 MIMAT0018948 C-302011-00 AAAGACUCUGCAAGAUGCCU -1.01744360848873 6.1693e-05 TRUE -3.10500591742549 0.023579 TRUE
hsa-miR-4433-3p MIMAT0018949 C-302012-00 ACAGGAGUGGGGGUGGGACAU -0.842019427210466 0.00023985 TRUE -1.23537194391469 0.40677 FALSE
hsa-miR-4433-5p MIMAT0020956 C-302013-00 CGUCCCACCCCCCACUCCUGU -1.14337035396948 3.6715e-05 TRUE -1.97664293733303 0.11887 TRUE
hsa-miR-4434 MIMAT0018950 C-302014-00 AGGAGAAGUAAAGUAGAA -0.883254828802553 0.00013963 TRUE -1.1657175196267 0.46329 FALSE
hsa-miR-4435 MIMAT0018951 C-302015-00 AUGGCCAGAGCUCACACAGAGG -0.883497505941514 0.00023985 TRUE -0.615152700112339 0.76975 FALSE
hsa-miR-4436a MIMAT0018952 C-302016-00 GCAGGACAGGCAGAAGUGGAU -1.04036408328386 3.9917e-05 TRUE -1.59208296058719 0.22566 FALSE
hsa-miR-4437 MIMAT0018953 C-302018-00 UGGGCUCAGGGUACAAAGGUU -1.08972765547642 3.9917e-05 TRUE -1.15841014023857 0.51048 FALSE
hsa-miR-4438 MIMAT0018956 C-302021-00 CACAGGCUUAGAAAAGACAGU -1.17220321847248 3.6715e-05 TRUE -1.92817351938145 0.11887 TRUE
hsa-miR-4440 MIMAT0018958 C-302023-00 UGUCGUGGGGCUUGCUGGCUUG -1.11752167173499 3.9917e-05 TRUE -2.33357733512522 0.08542 TRUE
hsa-miR-4441 MIMAT0018959 C-302024-00 ACAGGGAGGAGAUUGUA -1.2984552451679 1.5894e-05 TRUE -0.431268961949208 0.86349 FALSE
hsa-miR-4442 MIMAT0018960 C-302025-00 GCCGGACAAGAGGGAGG -0.97262245143818 8.3715e-05 TRUE -1.15721358729306 0.46329 FALSE
hsa-miR-4443 MIMAT0018961 C-302026-00 UUGGAGGCGUGGGUUUU -1.75283027769511 3.4785e-06 TRUE -2.08359341608655 0.11887 TRUE
hsa-miR-4445-5p MIMAT0018963 C-301976-00 AGAUUGUUUCUUUUGCCGUGCA -1.26374145331415 1.5894e-05 TRUE -4.01626597303824 0.0018396 TRUE
hsa-miR-4447 MIMAT0018966 C-302029-00 GGUGGGGGCUGUUGUUU -0.841752979683909 0.00023985 TRUE -2.88111133299715 0.028781 TRUE
hsa-miR-4449 MIMAT0018968 C-302031-00 CGUCCCGGGGCUGCGCGAGGCA -0.853462598263724 0.00023985 TRUE -1.80522351536343 0.1633 FALSE
hsa-miR-4450 MIMAT0018971 C-302034-00 UGGGGAUUUGGAGAAGUGGUGA -1.06492940641686 4.5608e-05 TRUE -2.95948317827462 0.014453 TRUE
hsa-miR-4451 MIMAT0018973 C-302037-00 UGGUAGAGCUGAGGACA -1.13976267989773 3.6715e-05 TRUE -0.526465448512174 0.86349 FALSE
hsa-miR-4452 MIMAT0018974 C-302038-00 UUGAAUUCUUGGCCUUAAGUGAU -0.813274313439393 0.00026644 TRUE -0.166636659928165 1 FALSE
hsa-miR-4453 MIMAT0018975 C-302039-00 GAGCUUGGUCUGUAGCGGUU -1.18208500406966 3.9917e-05 TRUE -2.62562177516204 0.050122 TRUE
hsa-miR-448 MIMAT0001532 C-300721-05 UUGCAUAUGUAGGAUGUCCCAU -1.39737830033137 0.00054279 FALSE -2.29949072457764 0.11887 TRUE
hsa-miR-449c MIMAT0010251 C-301488-00 UAGGCAGUGUAUUGCUAGCGGCUGU -0.977360548104279 0.00013963 TRUE -1.65073035658006 0.26604 FALSE
hsa-miR-4507 MIMAT0019044 C-302113-00 CUGGGUUGGGCUGGGCUGGG -1.08254852754089 0.015067 FALSE -2.63018823024416 0.11887 TRUE
hsa-miR-450a-3p MIMAT0022700 C-301907-00 AUUGGGGACAUUUUGCAUUCAU -1.3171609377358 0.00013793 TRUE -1.14626230328136 0.46329 FALSE
hsa-miR-451 MIMAT0001631 C-300734-05 AAACCGUUACCAUUACUGAGUU -1.43368456108961 8.3715e-05 TRUE -0.268670734386333 1 FALSE
hsa-miR-452 MIMAT0001635 C-300735-07 AACUGUUUGCAGAGGAAACUGA -0.355271404072044 0.12653 FALSE -2.45598627080639 0.050122 TRUE
hsa-miR-4525 MIMAT0019064 C-302136-00 GGGGGGAUGUGCAUGCUGGUU -1.29162472134399 0.00013793 TRUE -1.82359755370572 0.26604 FALSE
hsa-miR-4526 MIMAT0019065 C-302137-00 GCUGACAGCAGGGCUGGCCGCU -0.819545705994525 0.0021076 FALSE -3.08101976925394 0.057617 TRUE
hsa-miR-4527 MIMAT0019066 C-302138-00 UGGUCUGCAAAGAGAUGACUGU -1.48851753125946 3.9917e-05 TRUE -1.1928606551261 0.5811 FALSE
hsa-miR-4533 MIMAT0019072 C-302145-00 UGGAAGGAGGUUGCCGGACGCU -1.18624537355721 0.00016326 TRUE -0.593158084514742 0.86349 FALSE
hsa-miR-4536-3p MIMAT0020959 C-301930-00 UCGUGCAUAUAUCUACCACAU -1.07232143191926 0.00054279 FALSE -3.00264840143944 0.014453 TRUE
hsa-miR-4536-5p MIMAT0019078 C-301929-00 UGUGGUAGAUAUAUGCACGAU -1.31712298567513 0.00013963 TRUE -1.61271864964865 0.20114 FALSE
hsa-miR-4538 MIMAT0019081 C-302154-00 GAGCUUGGAUGAGCUGGGCUGA -1.22689177781842 0.00013963 TRUE -1.39982249594569 0.5811 FALSE
hsa-miR-4539 MIMAT0019082 C-302155-00 GCUGAACUGGGCUGAGCUGGGC -0.662063245722664 0.0074787 FALSE -2.55330760069272 0.11887 TRUE
hsa-miR-4632-5p MIMAT0022977 C-302499-00 GAGGGCAGCGUGGGUGUGGCGGA -0.597712246032446 0.015067 FALSE -2.79546040686595 0.057617 TRUE
hsa-miR-4642 MIMAT0019702 C-302175-00 AUGGCAUCGUCCCCUGGUGGCU -1.24506307785847 0.00013963 TRUE -1.87231348016783 0.26604 FALSE
hsa-miR-4645-3p MIMAT0019706 C-302179-00 AGACAGUAGUUCUUGCCUGGUU -1.12025038846698 0.00026644 TRUE -1.08522858184346 0.5811 FALSE
hsa-miR-4650-3p MIMAT0019714 C-302184-00 AGGUAGAAUGAGGCCUGACAU -1.52761158686618 3.9917e-05 TRUE -2.47248261479947 0.11887 TRUE
hsa-miR-4651 MIMAT0019715 C-302187-00 CGGGGUGGGUGAGGUCGGGC -1.12142324138952 0.00023985 TRUE -1.06587157649805 0.5811 FALSE
hsa-miR-4652-5p MIMAT0019716 C-302188-00 AGGGGACUGGUUAAUAGAACUA -1.12850660881293 0.00023985 TRUE -0.668591975163071 0.86349 FALSE
hsa-miR-4655-5p MIMAT0019721 C-302194-00 CACCGGGGAUGGCAGAGGGUCG -1.21402640640325 0.00016326 TRUE -1.71020871463468 0.40677 FALSE
hsa-miR-466 MIMAT0015002 C-301675-00 AUACACAUACACGCAACACACAU -1.57268812194273 1.5894e-05 TRUE -1.36589716672211 0.46329 FALSE
hsa-miR-4664-3p MIMAT0019738 C-302210-00 CUUCCGGUCUGUGAGCCCCGUC -1.12808833805518 8.3715e-05 TRUE -1.3144620182497 0.26604 FALSE
hsa-miR-4664-5p MIMAT0019737 C-302209-00 UGGGGUGCCCACUCCGCAAGUU -1.35541980608348 3.6715e-05 TRUE -0.623887404733994 0.76864 FALSE
hsa-miR-4665-5p MIMAT0019739 C-302211-00 CUGGGGGACGCGUGAGCGCGAGC -1.14650290801351 6.1693e-05 TRUE -2.55003959556736 0.014453 TRUE
hsa-miR-4666b MIMAT0022485 C-302595-00 UUGCAUGUCAGAUUGUAAUUCCC -1.25134263280118 0.0053924 FALSE -1.96334534104703 0.11887 TRUE
hsa-miR-4668-5p MIMAT0019745 C-302216-00 AGGGAAAAAAAAAAGGAUUUGUC -1.06833102929774 0.00013793 TRUE -1.46510395349218 0.1633 FALSE
hsa-miR-4672 MIMAT0019754 C-302224-00 UUACACAGCUGGACAGAGGCA -1.69132941190395 1.5655e-05 TRUE -1.82970618393803 0.11887 TRUE
hsa-miR-4674 MIMAT0019756 C-302226-00 CUGGGCUCGGGACGCGCGGCU -1.30671632029371 3.9917e-05 TRUE -1.87257075861882 0.08542 TRUE
hsa-miR-4675 MIMAT0019757 C-302227-00 GGGGCUGUGAUUGACCAGCAGG -0.49750400822998 0.015067 FALSE -1.65778479186002 0.11887 TRUE
hsa-miR-4677-5p MIMAT0019760 C-302231-00 UUGUUCUUUGGUCUUUCAGCCA -1.01207284849144 0.00013963 TRUE -2.02433296093174 0.1633 FALSE
hsa-miR-4678 MIMAT0019762 C-302232-00 AAGGUAUUGUUCAGACUUAUGA -0.678062145099685 0.0021076 FALSE -1.8265679594388 0.11887 TRUE
hsa-miR-4682 MIMAT0019767 C-302236-00 UCUGAGUUCCUGGAGCCUGGUCU -0.95136903371094 0.00023985 TRUE -0.279156377102257 1 FALSE
hsa-miR-4683 MIMAT0019768 C-302237-00 UGGAGAUCCAGUGCUCGCCCGAU -1.03845589118353 0.00013793 TRUE -2.39905380190628 0.023579 TRUE
hsa-miR-4684-3p MIMAT0019770 C-302239-00 UGUUGCAAGUCGGUGGAGACGU -0.997924294092217 0.00016326 TRUE -1.70225287410888 0.1633 FALSE
hsa-miR-4687-3p MIMAT0019775 C-302242-00 UGGCUGUUGGAGGGGGCAGGC -1.08006757648135 9.6971e-05 TRUE -2.49518358442824 0.023579 TRUE
hsa-miR-4688 MIMAT0019777 C-302244-00 UAGGGGCAGCAGAGGACCUGGG -0.933026739975212 0.00023985 TRUE -2.48777268680185 0.023579 TRUE
hsa-miR-4689 MIMAT0019778 C-302245-00 UUGAGGAGACAUGGUGGGGGCC -1.02151466268037 0.00023985 TRUE -1.54092925086873 0.1633 FALSE
hsa-miR-4692 MIMAT0019783 C-302250-00 UCAGGCAGUGUGGGUAUCAGAU -0.988783938058944 0.00016326 TRUE -1.1486808400672 0.40677 FALSE
hsa-miR-4693-3p MIMAT0019785 C-302252-00 UGAGAGUGGAAUUCACAGUAUUU -1.44962435716591 3.6715e-05 TRUE -1.73885084830262 0.11887 TRUE
hsa-miR-4694-3p MIMAT0019787 C-302253-00 CAAAUGGACAGGAUAACACCU -0.93855714822229 0.00023985 TRUE -1.50626462839686 0.1633 FALSE
hsa-miR-4694-5p MIMAT0019786 C-302254-00 AGGUGUUAUCCUAUCCAUUUGC -0.952993076462483 0.00023985 TRUE -2.88415743782109 0.014453 TRUE
hsa-miR-4695-3p MIMAT0019789 C-302458-00 UGAUCUCACCGCUGCCUCCUUC -1.73712530730441 3.6715e-05 TRUE -2.61115419781241 0.11887 TRUE
hsa-miR-4696 MIMAT0019790 C-302255-00 UGCAAGACGGAUACUGUCAUCU -1.05967205505661 0.00013793 TRUE -3.0267965783108 0.009387 TRUE
hsa-miR-4697-5p MIMAT0019791 C-302257-00 AGGGGGCGCAGUCACUGACGUG -1.49838261147195 1.5894e-05 TRUE -1.93121149945073 0.08542 TRUE
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hsa-miR-4699-5p MIMAT0019794 C-302259-00 AGAAGAUUGCAGAGUAAGUUCC -0.321333385517737 0.096607 FALSE -1.70896571432969 0.11887 TRUE
hsa-miR-4700-5p MIMAT0019796 C-302262-00 UCUGGGGAUGAGGACAGUGUGU -0.63878129737828 0.0046172 FALSE -2.49301512707352 0.023579 TRUE
hsa-miR-4701-5p MIMAT0019798 C-302460-00 UUGGCCACCACACCUACCCCUU -1.25407592715591 0.00016326 TRUE -2.10511844533172 0.1633 FALSE
hsa-miR-4706 MIMAT0019806 C-302269-00 AGCGGGGAGGAAGUGGGCGCUGCUU -0.640574202002897 0.0030028 FALSE -1.80378336355061 0.11887 TRUE
hsa-miR-4707-3p MIMAT0019808 C-302270-00 AGCCCGCCCCAGCCGAGGUUCU -0.833524657548794 0.00079918 FALSE -2.32407172887442 0.057617 TRUE
hsa-miR-4708-3p MIMAT0019810 C-302273-00 AGCAAGGCGGCAUCUCUCUGAU -0.969695371193823 0.00023985 TRUE -0.525873276306624 0.86349 FALSE
hsa-miR-4708-5p MIMAT0019809 C-302272-00 AGAGAUGCCGCCUUGCUCCUU -0.822684020528361 0.00079918 FALSE -2.10220660879154 0.08542 TRUE
hsa-miR-4709-3p MIMAT0019812 C-302275-00 UUGAAGAGGAGGUGCUCUGUAGC -0.66432740058703 0.0027607 FALSE -1.68675985049984 0.11887 TRUE
hsa-miR-4709-5p MIMAT0019811 C-302274-00 ACAACAGUGACUUGCUCUCCAA -1.08969801660567 9.6971e-05 TRUE -0.80626334250579 0.5811 FALSE
hsa-miR-4711-5p MIMAT0019816 C-302279-00 UGCAUCAGGCCAGAAGACAUGAG -0.502094584622719 0.015067 FALSE -2.22945919207469 0.057617 TRUE
hsa-miR-4712-3p MIMAT0019819 C-302282-00 AAUGAGAGACCUGUACUGUAU -1.26003058356888 3.9917e-05 TRUE -2.5282291027878 0.028781 TRUE
hsa-miR-4713-5p MIMAT0019820 C-302283-00 UUCUCCCACUACCAGGCUCCCA -1.41056492413791 3.6715e-05 TRUE 0.152837140204165 1 FALSE
hsa-miR-4714-5p MIMAT0019822 C-302286-00 AACUCUGACCCCUUAGGUUGAU -0.971641326370144 0.00023985 TRUE -1.9820676345786 0.08542 TRUE
hsa-miR-4715-3p MIMAT0019825 C-302288-00 GUGCCACCUUAACUGCAGCCAAU -0.831711497711227 0.0014577 FALSE -1.64639738941666 0.11887 TRUE
hsa-miR-4720-3p MIMAT0019834 C-302297-00 UGCUUAAGUUGUACCAAGUAU -0.267039361511682 0.37761 FALSE -2.41942301448004 0.057617 TRUE
hsa-miR-4726-3p MIMAT0019846 C-302309-00 ACCCAGGUUCCCUCUGGCCGCA -1.05457626001572 0.0046172 FALSE -1.96757030993053 0.11887 TRUE
hsa-miR-4726-5p MIMAT0019845 C-302310-00 AGGGCCAGAGGAGCCUGGAGUGG -0.548731137329315 0.061384 FALSE -2.20367296738285 0.11887 TRUE
hsa-miR-4730 MIMAT0019852 C-302314-00 CUGGCGGAGCCCAUUCCAUGCCA -1.14323623131763 0.0021076 FALSE -3.22072847594229 0.014453 TRUE
hsa-miR-4731-3p MIMAT0019854 C-302316-00 CACACAAGUGGCCCCCAACACU -0.715286408900071 0.021994 FALSE -2.11972721193743 0.11887 TRUE
hsa-miR-4733-5p MIMAT0019857 C-302319-00 AAUCCCAAUGCUAGACCCGGUG -0.918486094585803 0.0074787 FALSE -2.80327741332156 0.023579 TRUE
hsa-miR-4740-3p MIMAT0019870 C-302329-00 GCCCGAGAGGAUCCGUCCCUGC -0.824911201381423 0.015067 FALSE -3.46216635615516 0.014453 TRUE
hsa-miR-4743-5p MIMAT0019874 C-302462-00 UGGCCGGAUGGGACAGGAGGCAU -1.02760222969445 0.00061109 FALSE -2.22597648616421 0.11887 TRUE
hsa-miR-4745-3p MIMAT0019879 C-302464-00 UGGCCCGGCGACGUCUCACGGUC -1.23742515486855 0.00016326 TRUE -2.78131955234324 0.08542 TRUE
hsa-miR-4747-3p MIMAT0019883 C-302339-00 AAGGCCCGGGCUUUCCUCCCAG -0.465231590374108 0.12653 FALSE -2.90430878110698 0.023579 TRUE
hsa-miR-4747-5p MIMAT0019882 C-302340-00 AGGGAAGGAGGCUUGGUCUUAG -0.431504547805173 0.17522 FALSE -1.91877072137694 0.12226 TRUE
hsa-miR-4748 MIMAT0019884 C-302341-00 GAGGUUUGGGGAGGAUUUGCU -0.555957276676544 0.061384 FALSE -2.01827086334852 0.11887 TRUE
hsa-miR-4750-3p MIMAT0022979 C-302491-00 CCUGACCCACCCCCUCCCGCAG -0.714754040609532 0.0074787 FALSE -2.39203721905178 0.11887 TRUE
hsa-miR-4755-5p MIMAT0019895 C-302349-00 UUUCCCUUCAGAGCCUGGCUUU -0.539113669488979 0.061384 FALSE -2.80807175968132 0.057617 TRUE
hsa-miR-4760-5p MIMAT0019906 C-302359-00 UUUAGAUUGAACAUGAAGUUAG -0.823743933447296 0.015067 FALSE -2.78675399181231 0.028781 TRUE
hsa-miR-4768-5p MIMAT0019920 C-302372-00 AUUCUCUCUGGAUCCCAUGGAU -0.784576616178355 0.061384 FALSE -2.06931455868509 0.11887 TRUE
hsa-miR-4774-3p MIMAT0019930 C-302383-00 AUUGCCUAACAUGUGCCAGAA -0.980156502965659 0.03164 FALSE -1.92072766628618 0.12226 TRUE
hsa-miR-4778-3p MIMAT0019937 C-302393-00 UCUUCUUCCUUUGCAGAGUUGA -0.468380465892249 0.17522 FALSE -2.12161516444605 0.11887 TRUE
hsa-miR-4778-5p MIMAT0019936 C-302392-00 AAUUCUGUAAAGGAAGAAGAGG -0.108428651324849 1 FALSE 2.20881646867654 0.08542 TRUE
hsa-miR-4782-3p MIMAT0019945 C-302398-00 UGAUUGUCUUCAUAUCUAGAAC -0.415227659905038 0.32544 FALSE -1.91949188729733 0.11887 TRUE
hsa-miR-4792 MIMAT0019964 C-302418-00 CGGUGAGCGCUCGCUGGC -0.681007711978918 0.096607 FALSE -2.3586952181417 0.057617 TRUE
hsa-miR-4799-5p MIMAT0019976 C-302431-00 AUCUAAAUGCAGCAUGCCAGUC -0.362222805879938 0.32544 FALSE -1.88523388837028 0.11887 TRUE
hsa-miR-4800-5p MIMAT0019978 C-302435-00 AGUGGACCGAGGAAGGAAGGA -1.32275981315377 0.0074787 FALSE -2.73500556024618 0.028781 TRUE
hsa-miR-4804-3p MIMAT0019985 C-302441-00 UGCUUAACCUUGCCCUCGAAA -0.336610566496397 0.37761 FALSE -2.24438580605872 0.11887 TRUE
hsa-miR-486-3p MIMAT0004762 C-301211-01 CGGGGCAGCUCAGUACAGGAU -0.915928947716196 0.0027607 FALSE -1.90219636227184 0.11887 TRUE
hsa-miR-487a MIMAT0002178 C-300747-03 AAUCAUACAGGGACAUCCAGUU -0.747164545262154 0.015067 FALSE -2.42832566173827 0.040079 TRUE
hsa-miR-488 MIMAT0004763 C-301189-01 UUGAAAGGCUAUUUCUUGGUC -0.908290335869122 0.01741 FALSE -2.18110128296813 0.11887 TRUE
hsa-miR-491-3p MIMAT0004765 C-301091-01 CUUAUGCAAGAUUCCCUUCUAC -1.62232250510605 0.00023985 TRUE -1.07582371390113 0.46329 FALSE
hsa-miR-492 MIMAT0002812 C-300757-05 AGGACCUGCGGGACAAGAUUCUU -0.468584149908068 0.061384 FALSE -2.72511166766836 0.014453 TRUE
hsa-miR-494 MIMAT0002816 C-300761-05 UGAAACAUACACGGGAAACCUC -0.970219284972552 0.0021076 FALSE -3.24114885056762 0.014453 TRUE
hsa-miR-499b-3p MIMAT0019898 C-302351-00 AACAUCACUGCAAGUCUUAACA -0.450448811655319 0.10991 FALSE -2.12877293491975 0.11887 TRUE
hsa-miR-5001-3p MIMAT0021022 C-302470-00 UUCUGCCUCUGUCCAGGUCCUU -1.33428639345599 0.00013793 TRUE -1.54637406738355 0.40677 FALSE
hsa-miR-5003-5p MIMAT0021025 C-302474-00 UCACAACAACCUUGCAGGGUAGA -1.32073825957867 0.00013793 TRUE -1.18738346839705 0.51579 FALSE
hsa-miR-5004-5p MIMAT0021027 C-302477-00 UGAGGACAGGGCAAAUUCACGA -1.00354080968358 0.00079918 FALSE -3.14572597959306 0.057617 TRUE
hsa-miR-5006-5p MIMAT0021033 C-302479-00 UUGCCAGGGCAGGAGGUGGAA -1.29090326952253 0.00013963 TRUE -1.67173993218432 0.40677 FALSE
hsa-miR-501-3p MIMAT0004774 C-301167-01 AAUGCACCCGGGCAAGGAUUCU -0.0731774010060508 1 FALSE 1.96439959148781 0.057617 TRUE
hsa-miR-5087 MIMAT0021079 C-301942-00 GGGUUUGUAGCUUUGCUGGCAUG -0.359393924285983 0.10991 FALSE -1.78188598696404 0.11887 TRUE
hsa-miR-509-5p MIMAT0004779 C-301166-01 UACUGCAGACAGUGGCAAUCA -1.74945283553728 0.00013793 TRUE -2.47315672999895 0.081661 TRUE
hsa-miR-5092 MIMAT0021084 C-302456-00 AAUCCACGCUGAGCUUGGCAUC -1.18967239061038 0.00023985 TRUE -1.511756387148 0.46329 FALSE
hsa-miR-513a-5p MIMAT0002877 C-300844-07 UUCACAGGGAGGUGUCAU -1.05997050839063 0.0074787 FALSE -2.37670537648159 0.11887 TRUE
hsa-miR-513c-3p MIMAT0022728 C-301908-00 UAAAUUUCACCUUUCUGAGAAGA -0.803025559359186 0.0046172 FALSE -2.73190794276724 0.014453 TRUE
hsa-miR-514 MIMAT0002883 C-300851-07 AUUGACACUUCUGUGAGUAGA -0.348236527420602 0.12653 FALSE -1.56224654603507 0.11887 TRUE
hsa-miR-516a-5p MIMAT0004770 C-301104-01 UUCUCGAGGAAAGAAGCACUUUC -0.681407959396855 0.0046172 FALSE -2.18673664105892 0.11887 TRUE
hsa-miR-517a MIMAT0002852 C-300811-05 AUCGUGCAUCCCUUUAGAGUGU -1.09820612826732 0.0018747 FALSE -2.32535259864992 0.08542 TRUE
hsa-miR-517b-3p MIMAT0002857 C-300817-06 AUCGUGCAUCCCUUUAGAGUGU -1.68014170163936 3.9917e-05 TRUE -1.45577777456063 0.26604 FALSE
hsa-miR-517c MIMAT0002866 C-300832-03 AUCGUGCAUCCUUUUAGAGUGU -1.39967029576568 0.00054279 FALSE -3.92792989935189 0.009387 TRUE
hsa-miR-518a-5p MIMAT0005457 C-301099-01 CUGCAAAGGGAAGCCCUUUC -1.69701165144962 0.00013963 TRUE -3.84851299481868 0.014453 TRUE
hsa-miR-518b MIMAT0002844 C-300798-03 CAAAGCGCUCCCCUUUAGAGGU -1.15359484149699 0.00087976 FALSE -2.22045683232246 0.08542 TRUE
hsa-miR-518c* MIMAT0002847 C-300804-03 UCUCUGGAGGGAAGCACUUUCUG -1.15870379627599 0.0014577 FALSE -3.20841244988613 0.014453 TRUE
hsa-miR-518d-5p MIMAT0005456 C-301100-01 CUCUAGAGGGAAGCACUUUCUG -0.509493211764305 0.54004 FALSE -2.82765759572384 0.081661 TRUE
hsa-miR-5192 MIMAT0021123 C-302496-00 AGGAGAGUGGAUUCCAGGUGGU -0.929717635688366 0.0014577 FALSE -4.01918995190962 0.014453 TRUE
hsa-miR-5196-5p MIMAT0021128 C-301981-00 AGGGAAGGGGACGAGGGUUGGG -1.16761124143466 3.6715e-05 TRUE -2.56840698714633 0.040079 TRUE
hsa-miR-520a-3p MIMAT0002834 C-300788-03 AAAGUGCUUCCCUUUGGACUGU 0.0374069999290813 1 FALSE 2.98674734617433 0.08542 TRUE
hsa-miR-520c-3p MIMAT0002846 C-300803-05 AAAGUGCUUCCUUUUAGAGGGU -0.199389168688778 0.37761 FALSE -1.76230191681356 0.11887 TRUE
hsa-miR-520h MIMAT0002867 C-300833-03 ACAAAGUGCUUCCCUUUAGAGU -0.694676795373559 0.015067 FALSE -2.26960151079303 0.08542 TRUE
hsa-miR-532-5p MIMAT0002888 C-300867-01 CAUGCCUUGAGUGUAGGACCGU -0.687783861572295 0.021994 FALSE -3.38518185188287 0.014453 TRUE
hsa-miR-539-3p MIMAT0022705 C-301909-00 AUCAUACAAGGACAAUUUCUUU -0.712513192949551 0.0074787 FALSE -1.7777539713116 0.12226 TRUE
hsa-miR-544b MIMAT0015004 C-301677-00 ACCUGAGGUUGUGCAUUUCUAA -1.14820342901038 3.9917e-05 TRUE -0.449549813604399 0.91039 FALSE
hsa-miR-548ab MIMAT0018928 C-301990-00 AAAAGUAAUUGUGGAUUUUGCU -0.602579302030159 0.0021076 FALSE -2.46432616915756 0.057617 TRUE
hsa-miR-548ac MIMAT0018938 C-302001-00 CAAAAACCGGCAAUUACUUUUG -0.979633570213558 6.1693e-05 TRUE -2.0217602235335 0.11887 TRUE
hsa-miR-548ae MIMAT0018954 C-302019-00 CAAAAACUGCAAUUACUUUCA -0.606375099488669 0.0030028 FALSE -2.77725501966519 0.057617 TRUE
hsa-miR-548ah-3p MIMAT0020957 C-302036-00 CAAAAACUGCAGUUACUUUUGC -0.668405768437197 0.0014577 FALSE -2.22611084098903 0.081661 TRUE
hsa-miR-548at-5p MIMAT0022277 C-302544-00 AAAAGUUAUUGCGGUUUUGGCU -0.0453519642557928 1 FALSE -1.8924808826669 0.11887 TRUE
hsa-miR-548au-3p MIMAT0022292 C-302561-00 UGGCAGUUACUUUUGCACCAG -1.52595082150064 0.0021076 FALSE -3.17672563043804 0.014453 TRUE
hsa-miR-548ax MIMAT0022474 C-302582-00 AGAAGUAAUUGCGGUUUUGCCA -0.564257743083232 0.10991 FALSE -2.34784280477006 0.057617 TRUE
hsa-miR-548ay-5p MIMAT0025452 C-302660-00 AAAAGUAAUUGUGGUUUUUGC -0.653127591660778 0.021994 FALSE -3.23819702467989 0.014453 TRUE
hsa-miR-548h-3p MIMAT0022723 C-301888-00 CAAAAACCGCAAUUACUUUUGCA -1.06047561824622 0.00054279 FALSE -2.88715465104665 0.014453 TRUE
hsa-miR-548l MIMAT0005889 C-301353-00 AAAAGUAUUUGCGGGUUUUGUC -0.59227174574884 0.061384 FALSE -2.37472439626248 0.11887 TRUE
hsa-miR-548s MIMAT0014987 C-301658-00 AUGGCCAAAACUGCAGUUAUUUU -0.871664637647317 0.00054279 FALSE -2.25194852231406 0.11887 TRUE
hsa-miR-549 MIMAT0003333 C-300991-01 UGACAACUAUGGAUGAGCUCU -0.71851748320711 0.01741 FALSE -2.02535291589875 0.12226 TRUE
hsa-miR-550b-2-5p MIMAT0022737 C-301971-00 AUGUGCCUGAGGGAGUAAGACA -0.509912734915377 0.0074787 FALSE -1.84020688668008 0.12226 TRUE
hsa-miR-5580-5p MIMAT0022273 C-302541-00 UGCUGGCUCAUUUCAUAUGUGU -0.250725616752794 0.54004 FALSE -2.09116428366529 0.08542 TRUE
hsa-miR-5583-3p MIMAT0022282 C-302549-00 GAAUAUGGGUAUAUUAGUUUGG -0.580364168150873 0.10991 FALSE -2.828220915146 0.014453 TRUE
hsa-miR-5583-5p MIMAT0022281 C-302548-00 AAACUAAUAUACCCAUAUUCUG -0.74119839633839 0.050037 FALSE -2.77350973293048 0.014453 TRUE
hsa-miR-568 MIMAT0003232 C-300886-01 AUGUAUAAAUGUAUACACAC -0.546512240064326 0.050037 FALSE -2.16900241945777 0.11887 TRUE
hsa-miR-5681a MIMAT0022469 C-302576-00 AGAAAGGGUGGCAAUACCUCUU -0.554451480617061 0.10991 FALSE -2.10313927081946 0.11887 TRUE
hsa-miR-5681b MIMAT0022480 C-302589-00 AGGUAUUGCCACCCUUUCUAGU -0.990407574357977 0.015067 FALSE -2.24966625727449 0.11887 TRUE
hsa-miR-5685 MIMAT0022475 C-302583-00 ACAGCCCAGCAGUUAUCACGGG -1.10866668617995 0.0099219 FALSE -1.81151890217456 0.11887 TRUE
hsa-miR-5686 MIMAT0022477 C-302586-00 UAUCGUAUCGUAUUGUAUUGU -0.618603205233964 0.096607 FALSE -3.26787707054355 0.014453 TRUE
hsa-miR-5687 MIMAT0022478 C-302587-00 UUAGAACGUUUUAGGGUCAAAU -0.4136100982672 0.25618 FALSE -1.96140285293105 0.11887 TRUE
hsa-miR-5688 MIMAT0022479 C-302588-00 UAACAAACACCUGUAAAACAGC -0.496708860788786 0.17522 FALSE -2.54610797665859 0.028781 TRUE
hsa-miR-5689 MIMAT0022481 C-302590-00 AGCAUACACCUGUAGUCCUAGA -0.623295340978942 0.089234 FALSE -2.01329320718309 0.11887 TRUE
hsa-miR-5692a MIMAT0022484 C-302593-00 CAAAUAAUACCACAGUGGGUGU -0.71714659454192 0.061384 FALSE -2.47331051365896 0.057617 TRUE
hsa-miR-5692c MIMAT0022476 C-302584-00 AAUAAUAUCACAGUAGGUGUAC -0.930027776637268 0.021994 FALSE -2.41733401849822 0.057617 TRUE
hsa-miR-5697 MIMAT0022490 C-302600-00 UCAAGUAGUUUCAUGAUAAAGG -0.509179181511475 0.17522 FALSE -1.87679966081257 0.11887 TRUE
hsa-miR-5701 MIMAT0022494 C-302604-00 UUAUUGUCACGUUCUGAUU -0.713050083304961 0.061384 FALSE -2.19998791399188 0.081661 TRUE
hsa-miR-5702 MIMAT0022495 C-302605-00 UGAGUCAGCAACAUAUCCCAUG -0.634695457873147 0.089234 FALSE -2.91461280705682 0.014453 TRUE
hsa-miR-571 MIMAT0003236 C-300890-01 UGAGUUGGCCAUCUGAGUGAG -1.04012448788134 0.00016326 TRUE -1.0680220266461 0.5811 FALSE
hsa-miR-574-3p MIMAT0003239 C-300893-03 CACGCUCAUGCACACACCCACA -1.4521414321912 0.0018747 FALSE -2.74091004364483 0.057617 TRUE
hsa-miR-578 MIMAT0003243 C-300897-01 CUUCUUGUGCUCUAGGAUUGU -0.525376007672939 0.038627 FALSE -2.14162436977285 0.081661 TRUE
hsa-miR-579 MIMAT0003244 C-300898-03 UUCAUUUGGUAUAAACCGCGAUU -1.2654167775587 0.0030028 FALSE -3.8111485398612 0.014453 TRUE
hsa-miR-582-5p MIMAT0003247 C-300901-01 UUACAGUUGUUCAACCAGUUACU -1.2010641323251 0.00070025 FALSE -2.60372535467359 0.040079 TRUE
hsa-miR-586 MIMAT0003252 C-300906-01 UAUGCAUUGUAUUUUUAGGUCC -0.445099473295375 0.10991 FALSE -3.97498411008623 0.014453 TRUE
hsa-miR-593* MIMAT0003261 C-300917-01 AGGCACCAGCCAGGCAUUGCUCAGC -1.46368716545378 0.00023985 TRUE -1.69498877920483 0.1633 FALSE
hsa-miR-606 MIMAT0003274 C-300931-01 AAACUACUGAAAAUCAAAGAU -0.637631782545375 0.32544 FALSE -2.73649791406254 0.11887 TRUE
hsa-miR-607 MIMAT0003275 C-300932-01 GUUCAAAUCCAGAUCUAUAAC -0.096398469481977 1 FALSE 2.3242183673772 0.11887 TRUE
hsa-miR-6071 MIMAT0023696 C-302625-00 UUCUGCUGCCGGCCAAGGC -0.528822533996229 0.12653 FALSE -2.1934583463063 0.11887 TRUE
hsa-miR-6075 MIMAT0023700 C-302629-00 ACGGCCCAGGCGGCAUUGGUG -0.592038077604373 0.037103 FALSE -2.63925181780449 0.057617 TRUE
hsa-miR-608 MIMAT0003276 C-300933-01 AGGGGUGGUGUUGGGACAGCUCCGU -1.41476375494069 9.6971e-05 TRUE -1.32647981772413 0.22566 FALSE
hsa-miR-6080 MIMAT0023705 C-302634-00 UCUAGUGCGGGCGUUCCCG -0.377302781648075 0.17522 FALSE -3.12142545628473 0.023579 TRUE
hsa-miR-6081 MIMAT0023706 C-302635-00 AGGAGCAGUGCCGGCCAAGGCGCC -1.07161737179969 0.0018747 FALSE -2.06272320366808 0.11887 TRUE
hsa-miR-6086 MIMAT0023711 C-302640-00 GGAGGUUGGGAAGGGCAGAG -0.556948350994301 0.040903 FALSE -2.86501870739423 0.028781 TRUE
hsa-miR-6133 MIMAT0024617 C-302655-00 UGAGGGAGGAGGUUGGGUA -1.00026187079406 0.0021076 FALSE -3.11682515905473 0.014453 TRUE
hsa-miR-617 MIMAT0003286 C-300943-01 AGACUUCCCAUUUGAAGGUGGC -1.41203659250412 0.00023985 TRUE -0.966712399788375 0.51579 FALSE
hsa-miR-619 MIMAT0003288 C-300945-01 GACCUGGACAUGUUUGUGCCCAGU 0.0866202298806936 1 FALSE 2.48494644624597 0.014453 TRUE
hsa-miR-620 MIMAT0003289 C-300946-01 AUGGAGAUAGAUAUAGAAAU -0.746644845920626 0.096607 FALSE -3.35303260797096 0.057617 TRUE
hsa-miR-621 MIMAT0003290 C-300947-01 GGCUAGCAACAGCGCUUACCU -0.524135944687041 0.49143 FALSE -3.56178952288145 0.023579 TRUE
hsa-miR-624* MIMAT0003293 C-300950-01 UAGUACCAGUACCUUGUGUUCA -1.18323865292578 8.3715e-05 TRUE -2.08818623024311 0.11887 TRUE
hsa-miR-627 MIMAT0003296 C-300953-01 GUGAGUCUCUAAGAAAAGAGGA -1.05366486573687 0.00016326 TRUE -1.71256975426944 0.22566 FALSE
hsa-miR-631 MIMAT0003300 C-300957-01 AGACCUGGCCCAGACCUCAGC -2.01925344204044 3.9917e-05 TRUE -1.07267199301577 0.51048 FALSE
hsa-miR-634 MIMAT0003304 C-300961-01 AACCAGCACCCCAACUUUGGAC -1.30123850604998 0.00016067 TRUE -0.64623077279342 0.76864 FALSE
hsa-miR-638 MIMAT0003308 C-300965-01 AGGGAUCGCGGGCGGGUGGCGGCCU -0.639193662554625 0.03164 FALSE -1.99612853656179 0.12226 TRUE
hsa-miR-642a-3p MIMAT0020924 C-301902-00 AGACACAUUUGGAGAGGGAACC -0.669360409839209 0.0099219 FALSE -2.67786191538987 0.023579 TRUE
hsa-miR-642b-5p MIMAT0022736 C-301970-00 GGUUCCCUCUCCAAAUGUGUCU -0.982372985036737 6.1693e-05 TRUE -2.91448575097456 0.023579 TRUE
hsa-miR-644 MIMAT0003314 C-300971-01 AGUGUGGCUUUCUUAGAGC -1.1328764594198 0.0014577 FALSE -2.28201156273226 0.12226 TRUE
hsa-miR-646 MIMAT0003316 C-300973-01 AAGCAGCUGCCUCUGAGGC -1.37335174868112 3.9917e-05 TRUE -1.88378259141162 0.1633 FALSE
hsa-miR-647 MIMAT0003317 C-300974-01 GUGGCUGCACUCACUUCCUUC -0.662202123721489 0.015067 FALSE -2.34112755480514 0.057617 TRUE
hsa-miR-6499-3p MIMAT0025451 C-302659-00 AGCAGUGUUUGUUUUGCCCACA -0.78931105472599 0.0099219 FALSE -2.42776308682332 0.08542 TRUE
hsa-miR-650 MIMAT0003320 C-300977-01 AGGAGGCAGCGCUCUCAGGAC -1.32232002772507 0.00054279 FALSE -2.38532145199764 0.11887 TRUE
hsa-miR-6503-3p MIMAT0025463 C-302671-00 GGGACUAGGAUGCAGACCUCC -0.701857748301807 0.01741 FALSE -2.26797239631951 0.08542 TRUE
hsa-miR-6503-5p MIMAT0025462 C-302670-00 AGGUCUGCAUUCAAAUCCCCAGA -1.28829279156107 0.00061109 FALSE -4.16301032924927 0.009387 TRUE
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hsa-miR-6504-3p MIMAT0025465 C-302672-00 CAUUACAGCACAGCCAUUCU -0.219268298279075 0.49143 FALSE -2.3682663259571 0.08542 TRUE
hsa-miR-6505-3p MIMAT0025467 C-302675-00 UGACUUCUACCUCUUCCAAAG -1.41016990839787 0.00054279 FALSE -2.92045878806631 0.040079 TRUE
hsa-miR-6507-5p MIMAT0025470 C-302679-00 GAAGAAUAGGAGGGACUUUGU -0.637513482741369 0.03164 FALSE -2.64696299700191 0.057617 TRUE
hsa-miR-6514-3p MIMAT0025485 C-302693-00 CUGCCUGUUCUUCCACUCCAG -1.57253367763337 0.00023985 TRUE -0.857463656453242 0.72813 FALSE
hsa-miR-652-5p MIMAT0022709 C-301928-00 CAACCCUAGGAGAGGGUGCCAUUCA -0.590578760858739 0.01741 FALSE -2.04113601671663 0.11887 TRUE
hsa-miR-654-5p MIMAT0003330 C-300988-01 UGGUGGGCCGCAGAACAUGUGC -1.24102088307823 0.00054279 FALSE -4.37321715649902 0.0018396 TRUE
hsa-miR-659 MIMAT0003337 C-300994-01 CUUGGUUCAGGGAGGGUCCCCA -0.865338332757254 0.0053924 FALSE -2.2970254587848 0.12226 TRUE
hsa-miR-660-3p MIMAT0022711 C-301897-00 ACCUCCUGUGUGCAUGGAUUA -0.914364872105563 0.0018747 FALSE -2.7989676696545 0.028781 TRUE
hsa-miR-661 MIMAT0003324 C-300981-01 UGCCUGGGUCUCUGGCCUGCGCGU -0.966061272920722 0.0046172 FALSE -2.04789510522588 0.11887 TRUE
hsa-miR-664b-3p MIMAT0022272 C-302539-00 UUCAUUUGCCUCCCAGCCUACA -0.63588937093853 0.061384 FALSE -2.38779084523873 0.057617 TRUE
hsa-miR-671-5p MIMAT0003880 C-301000-03 AGGAAGCCCUGGAGGGGCUGGAG -1.01268622344544 0.00023985 TRUE -0.995050180707598 0.5811 FALSE
hsa-miR-6721-5p MIMAT0025852 C-302707-00 UGGGCAGGGGCUUAUUGUAGGAG -1.0522716562067 0.0021076 FALSE -2.86092601806193 0.028781 TRUE
hsa-miR-7 MIMAT0000252 C-300546-07 UGGAAGACUAGUGAUUUUGUUGU -0.833080606802588 0.0014577 FALSE -2.34382127982937 0.11887 TRUE
hsa-miR-718 MIMAT0012735 C-301486-00 CUUCCGCCCCGCCGGGCGUCG -0.712476270533885 0.0014577 FALSE -2.51689917044679 0.08542 TRUE
hsa-miR-744 MIMAT0004945 C-301242-01 UGCGGGGCUAGGGCUAACAGCA -1.31292964878657 0.0027607 FALSE -2.17130853543699 0.057617 TRUE
hsa-miR-744* MIMAT0004946 C-301241-01 CUGUUGCCACUAACCUCAACCU -0.909425861300587 3.9917e-05 TRUE -2.41920375944258 0.11887 TRUE
hsa-miR-764 MIMAT0010367 C-301640-00 GCAGGUGCUCACUUGUCCUCCU -1.1596052122796 6.1693e-05 TRUE -0.963991799367289 0.5811 FALSE
hsa-miR-767-3p MIMAT0003883 C-301003-01 UCUGCUCAUACCCCAUGGUUUCU -0.875815222995269 0.0021076 FALSE -2.87852305265755 0.009387 TRUE
hsa-miR-801 MI0005202 C-301014-01 GAUUGCUCUGCGUGCGGAAUCGAC -1.02838938735747 0.00023985 TRUE 0.128066636696993 1 FALSE
hsa-miR-873-3p MIMAT0022717 C-301921-00 GGAGACUGAUGAGUUCCCGGGA -0.45500701580676 0.050037 FALSE -2.17559760678154 0.08542 TRUE
hsa-miR-888* MIMAT0004917 C-301227-01 GACUGACACCUCUUUGGGUGAA -0.798719536763374 0.015067 FALSE -1.83668949541677 0.11887 TRUE
hsa-miR-940 MIMAT0004983 C-301269-01 AAGGCAGGGCCCCCGCUCCCC -1.31504996360232 0.00054279 FALSE -2.52010733193133 0.11887 TRUE
hsa-miR-96 MIMAT0000095 C-300514-07 UUUGGCACUAGCACAUUUUUGCU -0.788957233607577 0.0074787 FALSE -2.19234338350236 0.11527 TRUE
hsa-miR-99a MIMAT0000097 C-300516-03 AACCCGUAGAUCCGAUCUUGUG -0.986802247020601 0.0030028 FALSE -2.42723567464877 0.11887 TRUE
Legend
Antiviral effect
Proviral effect 
Note: Hits were selected using the following Local False Discovery Rate (lfdr) thresholds: 0.00027 in screen part 1 and 0.1226 in screen part 2. Positive log2 fold change values indicate a proviral effect of the miRNA on the 
HCV life cycle, while negative log2 fold change values indicate an antiviral effect. 
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1 Abstract
2
3 Objective: Infection of human hepatocytes by the hepatitis C virus (HCV) is a multistep 
4 process involving both viral and host factors. microRNAs (miRNAs) are small non-coding 
5 RNAs that post-transcriptionally regulate gene expression. Given that miRNAs were 
6 indicated to regulate between 30% and 75% of all human genes, we aimed to investigate the 
7 functional and regulatory role of miRNAs for the HCV life cycle. 
8 Design: To systematically reveal human miRNAs affecting the HCV life cycle, we performed 
9 a two-step functional high-throughput miRNA mimic screen in Huh7.5.1 cells infected with 
10 recombinant cell culture-derived HCV. miRNA targeting was then assessed using a 
11 combination of computational and functional approaches. 
12 Results: We uncovered miR-501-3p and miR-619-3p as novel modulators of HCV 
13 assembly/release. We discovered that these miRNAs regulate O-linked N-acetylglucosamine 
14 (O-GlcNAc) transferase (OGT) protein expression and identified OGT and O-GlcNAcylation 
15 as regulators of HCV morphogenesis and infectivity. Furthermore, increased OGT 
16 expression in patient-derived liver tissue was associated with HCV-induced liver disease and 
17 cancer.
18 Conclusion: miR-501-3p and miR-619-3p and their target OGT are previously undiscovered 
19 regulatory host factors for HCV assembly and infectivity. In addition to its effect on HCV 
20 morphogenesis, OGT may play a role in HCV-induced liver disease and 
21 hepatocarcinogenesis. 
22
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4
Significance of this study
1
What is already known about this subject?
 To establish chronic infection, the hepatitis C virus (HCV) hijacks cellular factors 
including microRNAs (miRNAs), known to post-transcriptionally regulate gene 
expression. 
 miRNAs may positively or negatively modulate HCV infection either by directly 
targeting the viral genome or indirectly by regulating virus-associated cellular 
pathways[1, 2].
What are the new findings?
 A functional miRNA mimic screen uncovered miR-501-3p and miR-619-3p to 
enhance late steps of HCV infection.
 miR-501-3p regulates the expression of O-linked N-acetylglucosamine transferase 
(OGT) at the protein level.
 Silencing of OGT expression or inhibition of O-linked N-acetylglucosaminylation (O-
GlcNAcylation) leads to an increase in the infectivity and size of HCV particles.
 OGT expression increases in patient-derived liver tissue during liver disease 
progression and cancer.
How might it impact on clinical practice in the foreseeable future?
 As upregulation of OGT and increased O-GlcNAcylation of proteins have been 
associated with various forms of cancer, OGT may play a dual role in HCV 
morphogenesis as well as pathogenesis of HCV-induced liver disease and 
carcinogenesis.
2
3
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5
1 Introduction 
2 Chronic hepatitis C is a major cause of chronic liver disease and hepatocellular carcinoma 
3 (HCC). Since the approval of pan-genotypic direct-acting antivirals (DAAs), it is considered a 
4 curable disease in more than 90% of treated patients. Nonetheless, an estimated 71 million 
5 individuals are still infected by the hepatitis C virus (HCV) and several challenges remain; 
6 viral cure reduces but does not eliminate the HCC risk in patients with advanced fibrosis[3], 
7 the majority of infected patients has limited access to therapy and DAA failure/viral 
8 resistance has been reported in a subset of patients[4, 5]. To overcome these limitations, 
9 approaches to target host factors involved in HCV infection and pathogenesis are 
10 developed[6, 7]. Interestingly, defined host factors that contribute to the establishment of 
11 chronic HCV infection and represent potential antiviral targets, e.g. epidermal growth factor 
12 receptor[8], also play a role in liver disease pathogenesis and represent candidate targets for 
13 treatment of advanced liver disease and HCC prevention[9]. Thus, uncovering host factors 
14 usurped by HCV not only contributes to a better understanding of virus-host interactions 
15 underlying the HCV life cycle but also to the identification of potential targets for treatment of 
16 liver disease and prevention of HCC. 
17 The establishment of various models to study HCV infection has shed light on the 
18 molecular mechanisms that govern the HCV life cycle, which can be subdivided into early 
19 steps, including viral entry, translation and replication as well as late steps, including 
20 assembly and release of new virions. Each step of the HCV replication cycle relies on 
21 specific virus-host interactions that involve host proteins and microRNAs (miRNAs)[7], small 
22 non-coding RNAs that regulate gene expression at the post-transcriptional level. One miRNA 
23 can target numerous messenger RNAs (mRNAs) by base-pairing with a complementary site 
24 that is typically located within the 3′ untranslated region (3′UTR) of the mRNA. Accumulating 
25 evidence indicates that miRNAs participate to HCV replication by exerting pro- or antiviral 
26 effects. The breakthrough discovery of the direct targeting of HCV by miR-122, the most 
27 abundant miRNA in the liver, revealed the crucial role of this miRNA for HCV 
28 translation/replication that contributes to progression to chronic HCV infection[1, 10]. miR-
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6
1 122 antisense oligonucleotides were subsequently developed as host-targeting antivirals[11, 
2 12]. Other miRNAs can indirectly target HCV by regulating host factors that participate in 
3 antiviral responses and immune surveillance[2, 13, 14]. Since up to 60% of all human 
4 protein-coding genes were reported to be under miRNA-mediated regulation and miRNAs 
5 are involved in basically every biological process, we hypothesized that miRNAs provide a 
6 tool for loss-of-function approaches to uncover novel HCV host factors. We performed 
7 genome-wide high-throughput modulation of the human miRNome and analyzed their impact 
8 on HCV infection by combining computational and functional approaches. 
9
10 Material and methods
11 Cells, cell culture conditions, viruses, virus purification, infectivity assays, miRNAs, 
12 antagomiRs, siRNAs, antibodies, immunoblot, immunocapture, electron microscopy 
13 analysis of viral particles and gene expression analysis in liver tissue are described in 
14 the Supplementary information.
15
16 Functional miRNA/siRNA screens. Huh7.5.1 cells were transfected with the miRIDIAN 
17 human miRNA mimic library (mIRBase 19) comprising more than 2000 mature miRNAs or 28 
18 ON-TARGETplus smart pool siRNAs (20 nM, Dharmacon) using Interferin HTS (Polyplus) in 
19 a 96-well format[8]. After 48h, a viability test (Presto Blue, Thermo Scientific) was performed 
20 prior to a two-step infection assay[15, 16, 17]. During part 1 of the protocol, 50 µL of HCV cell 
21 culture-derived particles (HCVcc, JcR2a) were incubated with cells during 4h. The inoculum 
22 was removed and cells were incubated with 150 µl of medium for 48h. In part 2, supernatants 
23 from part 1 cells were transferred onto naïve Huh7.5.1 cells and part 1 cells were lysed to 
24 determine luciferase activity[17, 18]. After 72h, part 2 cells were lysed to determine luciferase 
25 activity[17]. siCD81 (20 nM), antagomiR-122 (100 nM) and siApoE (20 nM) were used as 
26 positive controls[17]. A non-targeting siRNA with no sequence complementarity to any 
27 human gene or homology to any human miRNA was used as negative control. 
28
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7
1 Inhibitor treatment. Four hours following HCV RNA electroporation[8], Huh7.5.1 cells were 
2 incubated with vehicle or inhibitors of OGT (peracetylated 5-thio-N-acetylglucosamine 
3 (Ac45S-GlcNAc)[19]) or OGA (Thiamet G (Sigma))[20]. After 96h, supernatants were 
4 transferred onto naïve Huh7.5.1 cells for 72h prior to determination of luciferase activity while 
5 electroporated cells were lysed to determine luciferase activity. 
6
7 Gene expression analyses. Total RNA was purified[17] and transcribed into cDNA using 
8 Maxima reverse transcriptase (Thermo Scientific). GAPDH and OGT mRNA was detected by 
9 real time qPCR using iTaq™ Universal Probes Supermix (Bio-Rad) and TaqMan Gene 
10 Expression Assay (Thermo Scientific). Relative OGT/GAPDH gene expression was 
11 calculated by the ΔΔCt method[21]. 
12
13 Dual luciferase reporter gene assay. The human OGT 3'UTR sequence was retrieved from 
14 NCBI (NM_181672.2) and Ensembl genome browser (ENST00000373719.3). A fragment of 
15 the OGT 3′UTR (positions 3380-3837, NM_181672.2) (Thermo Fisher Scientific GENEART) 
16 was cloned between the NotI and XhoI sites downstream of a Renilla luciferase cassette in a 
17 psiCHECK2 plasmid (Promega). A mutated version of this construct (9-bp substitution in the 
18 predicted miR-501-3p target site) was generated as described[22]. The functionality of the 
19 OGT 3′UTR was assessed as described[23]. The miRIDIAN mimic negative control 1 was 
20 used as control. Renilla and firefly luciferase activity was assessed 48h after transfection into 
21 HeLa cells using Dual-Luciferase Reporter assay (Promega).
22
23 Bioinformatic and statistical analysis. Data analysis and statistical treatment for the 
24 miRNA mimic screen were performed in R (www.r-project.org). Cell measurement data used 
25 in further analysis were cell viability and luciferase activity. In total 26 sets of plates 
26 (performed in triplicate) were tested. The presence of multiple wells with negative and 
27 positive controls on each plate allowed stepwise normalization intra- and inter-plate. First, 
28 intra-plate zonal bias was examined and a model of median effects across the entire screen 
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8
1 determined using the median-polish algorithm[24] and all plates corrected accordingly. Then 
2 the dataset was examined for outlier plates, i.e. plates where all individual measurements 
3 correlate very poorly with the other remaining replicates. Three and 9 plates were excluded 
4 for part 1 and part 2 of the screen, respectively, based on poor median correlation (r < 0.7) 
5 so that the remaining plates correlation improved substantially (> 40%). Next, the plates were 
6 normalized inter replicates using the particularly robust quantile-quantile approach[25]. 
7 Finally, the data were tested using a moderated t-test (empirical Bayes shrinkage, R-
8 package limma[26]) for the null-hypothesis of no change of a given miRNA compared to the 
9 negative control. The resulting p-values for independent testing of each miRNA where 
10 corrected for the multiple testing situation and expressed as local false discovery rate (lfdr, 
11 R-package fdrtool[27]). The testing was performed independently for part 1 and 2 of the 
12 screen and candidate miRNAs selected for each part. For data from part 1, a lfdr threshold of 
13 0.00027 was used. Data from part 2 were subject to increase inherent stochastic noise and 
14 for this reason the minimum acceptable relative risk of false positives was increased to 
15 0.1226 (i.e. maximum 15% risk for each of the retained hits). 
16 Other datasets were analyzed using the two-tailed Mann-Whitney test, Wilcoxon test, 
17 Spearman correlation or the two-tailed unpaired t-test for data with normal distribution as 
18 assessed by D'Agostino and Pearson omnibus and Shapiro-Wilk normality tests (GraphPad 
19 Prism v.6 package).
20
21
22 Results
23 Genome-wide identification of human miRNAs affecting the HCV life cycle. We 
24 performed a genome-wide screen in human hepatoma Huh7.5.1 cells using a genomic 
25 miRNA mimics library and a two-step infection assay[17] with a luciferase reporter virus 
26 (JcR2a), which allowed us to functionally assess the role of miRNAs during the early steps 
27 (part 1 - viral entry/translation/replication) and the late steps (part 2 - viral 
28 assembly/release/infectivity) of the HCV life cycle (Fig. 1A). Silencing of CD81 and ApoE, 
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9
1 two essential host factors required for HCV entry or assembly, respectively, was performed 
2 in parallel using small interfering RNA (siRNA) as controls. Silencing of CD81 resulted in a 
3 reduction of HCV infection in part 1 and consequently in part 2 of the screen since reduced 
4 viral entry in the first part of the assay leads to a reduced production of viral particles (Fig. 
5 1B)[17]. Silencing of ApoE resulted in a marked inhibition of HCV infection only in part 2 of 
6 the assay, consistent with the role of ApoE in HCV assembly (Fig. 1B)[17]. The screen 
7 identified 427 miRNAs (corresponding to about 16% of the library) that significantly 
8 modulated HCV infection (lfdr < threshold, Supplementary Table 1 and Fig. 1C): 186 miRNAs 
9 affected HCV infection in part 1, 309 miRNAs affected HCV infection in part 2, including 68 
10 hits in part 1 and part 2. The limited number of part 1 and 2 hits may be due to the fact that a 
11 single miRNA may modulate the expression of several proteins, which may have different 
12 roles in the viral life cycle. Most hits were observed to dampen HCV infection independently 
13 of any significant alteration of cell viability (data not shown). The 186 miRNAs modulating the 
14 early steps of HCV infection all decreased viral infection. Among the 309 miRNAs that had 
15 an impact in part 2, 11 miRNAs increased HCV infection by at least 3-fold while 298 miRNAs 
16 inhibited HCV infection by at least 2.7-fold. Hits from the screen included the let-7 family[2, 
17 28], miR-27a[29] and miR-29 family[30] that were already shown to inhibit HCV infection, as 
18 well as miR-21[31] and miR-146a-5p[17] that were shown to stimulate HCV infection thus 
19 supporting the relevance of our findings. Collectively, our screen identified a set of miRNAs 
20 whose overexpression overall impairs HCV infection by affecting viral 
21 entry/translation/replication and/or virion assembly/egress/infectivity. 
22
23 miR-619-3p, miR-501-3p and OGT play a role in late steps of the HCV life cycle. We 
24 focused our analysis on miRNAs that modulate late steps of the HCV life cycle, as the 
25 molecular mechanisms of HCV assembly/release remain only partially understood. Our 
26 screen identified 241 miRNAs that modulated late steps without affecting early steps of 
27 infection: 11 miRNAs increased HCV infection while 230 miRNAs decreased HCV infection. 
28 Among the miRNAs that increased HCV infection, miR-140-3p, miR-501-3p, miR-619-3p and 
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10
1 miR-4778-5p have not yet been associated with HCV. Since they enhanced HCV infection in 
2 part 2 without affecting part 1, these miRNAs may target host genes that control virus 
3 assembly/egress/infectivity. We first confirmed the effect of these miRNAs in independent 
4 experiments using the same protocol as for the screen. Overexpression of miR-619-3p or 
5 miR-501-3p consistently led to an increase in the infection of progeny virions (Fig. 1D) while 
6 infection was decreased with progeny virions from antagomiR-transfected cells 
7 (Supplementary Figure S1A). miR-619-3p or miR-501-3p were thus selected for further 
8 investigation. To study the molecular mechanisms by which these miRNAs affect HCV 
9 infection, we generated a list of predicted miRNA targets using DIANA, TargetScan Human 
10 v6.2 and miRDB databases, and selected candidate targets based on their expression in our 
11 Huh7.5.1 cells as assessed by microarray (data not shown). Ingenuity Pathway Analysis 
12 enabled us to refine the gene list by selecting 28 genes involved in the following functional 
13 networks or pathways that contribute to the HCV life cycle[32, 33, 34]: lipid metabolism and 
14 cholesterol biosynthesis, protein maturation and processing at the endoplasmic reticulum 
15 (ER), components of the endosomal sorting complex, adipocyte biogenesis, cellular 
16 morphology and cell inflammation (Table 1). 
17 To assess whether knock-down of these 28 candidate targets affects virus 
18 production, we performed a siRNA-based screen using siRNA pools exhibiting strong 
19 silencing without cytotoxicity (Fig. 2). Silencing of CD81 and antagomiR-122 served as 
20 controls for part 1; knock-down of ApoE served as control for part 2 (Fig. 2). Hits were 
21 defined as genes whose knock-down modulated HCV infection in at least one part of the 
22 screen with high significance (Fig. 2, p-value < 0.0001, Mann-Whitney U-test). HCV 
23 entry/translation/replication was significantly modulated by silencing of PPP3CA, CEBPA, 
24 MID1, WDFY3, DCX and SLC35D1. HCV assembly/egress/infectivity was significantly 
25 modulated by knock-down of PPP3CA, CSDE1, GAN, USP37, CEBPA, MID1, WDFY3, DCX, 
26 MAPK9, SLC35D1, DCC, RNF144A, PPP2R2C and OGT. Strikingly, only the silencing of 
27 OGT was associated with an enhancement of HCV assembly/release/infectivity (p-value = 
28 0.0002), while that of the other hits was associated with reduced HCV infection (Fig. 2). 
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11
1 These results indicate that the down-regulation of OGT phenocopies the effect of miR-501-
2 3p and miR-619-3p on HCV infection (Fig. 2) and suggest OGT as a novel player in the HCV 
3 life cycle. 
4
5 miR-501-3p post-transcriptionally regulates OGT expression. To study whether miR-501-
6 3p and miR-619-3p target OGT, we analyzed OGT RNA and protein levels in Huh7.5.1 cells 
7 following overexpression of miR-501-3p or miR-619-3p. While neither miRNA had an impact 
8 on OGT RNA levels (Fig. 3A), up-regulation of miR-501-3p significantly decreased OGT 
9 protein expression by ~65% (Fig. 3B, p-value < 0.05, t-test). miR-619-3p also decreased 
10 OGT expression but less robustly than miR-501-3p (Fig. 3B), prompting us to focus our 
11 investigation on miR-501-3p. To assess whether OGT is a functional target of miR-501-3p, 
12 we subcloned a fragment of the OGT mRNA 3′UTR that harbors the predicted miR-501-3p 
13 target site in the Renilla luciferase expression cassette (RLuc) of a dual luciferase reporter 
14 construct. Co-transfection of miR-501-3p mimic with the wild-type 3’UTR reporter (RLuc wt 
15 OGT 3’UTR) significantly decreased luciferase activity as compared to the empty vector (Fig. 
16 3C, p-value < 0.05, t-test). In contrast, the repression of luciferase expression was lost when 
17 the reporter with mutated miR-501-3p binding site (RLuc mt OGT 3’UTR) was used (Fig. 3C). 
18 These data are consistent in indicating that miR-501-3p mediates post-transcriptional 
19 regulation of OGT.
20
21 O-GlcNAcylation modulates HCVcc infectivity. To investigate whether OGT modulates 
22 HCV assembly and/or infectivity, we determined infectious virus titer (TCID50) and HCV RNA 
23 levels to calculate the specific infectivity of HCVcc particles generated in OGT-silenced 
24 Huh7.5.1 cells. Interestingly, OGT-silencing led to a significant increase in the TCID50 and 
25 the specific infectivity of HCVcc (Fig. 4A, p-value < 0.05, Mann-Whitney test). Noteworthy, 
26 the effect of OGT on HCVcc infectivity was genotype-independent as demonstrated by 
27 increased infectivity of HCVcc bearing the envelope glycoproteins of genotypes 1a, 1b and 
28 2a upon OGT-silencing (Fig. 4B). We next sought to investigate how OGT could modulate 
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12
1 HCVcc infectivity. OGT is the only enzyme that catalyzes the addition of N-
2 acetylglucosamine (O-GlcNAc) to serine and threonine residues of proteins. Moreover, OGT 
3 has a scaffold function and promotes binding of proteins in multiprotein complexes[35]. To 
4 assess whether the enzymatic activity of OGT modulates HCVcc infectivity, we used 
5 pharmacological inhibitors of OGT (Ac45S-GlcNAc) or O-GlcNAcase (OGA) (Thiamet G), the 
6 OGT counterpart that removes O-GlcNAc (Fig. 4C). Ac45S-GlcNAc led to a significant 
7 enhancement of HCVcc infectivity in a dose-dependent manner, while the opposite effect 
8 was observed with Thiamet G (Fig. 4D, p-value < 0.05, Mann-Whitney test). Collectively, 
9 these results demonstrate that O-GlcNAcylation modulates HCVcc infectivity. 
10
11 OGT-silencing affects HCVcc biophysical properties and size distribution. To further 
12 assess how OGT may impact HCVcc morphogenesis, we analyzed the structural and 
13 biophysical properties of HCVcc produced in siCtrl- and siOGT-transfected Huh7.5.1 cells 
14 following iodixanol gradient ultracentrifugation. Silencing of OGT led to the production of 
15 more infectious HCVcc with higher density (Fig. 5A-B) as well as higher ApoE concentrations 
16 (Fig. 5C) suggesting that OGT/O-GlcNAcylation affects the biophysical properties of HCVcc. 
17 No change in apoB concentrations were observed between HCVcc produced from siCtrl- or 
18 siOGT-transfected cells (Fig. 5D), in line with the model that HCV lipoviroparticles contain 
19 several exchangeable ApoE molecules and one non-exchangeable apoB[36]. We also 
20 visualized HCVcc by electron microscopy (EM) following anti-E2 antibody 
21 immunocapture[36] to assess whether OGT-silencing had an impact on HCVcc size. Particle 
22 size distribution was assessed from a series of randomly acquired electron micrographs. A 
23 shift towards bigger sizes was observed for sucrose-cushion purified HCVcc generated in 
24 OGT-silenced Huh7.5.1 cells as compared to control HCVcc (Fig. 6A-B). This shift was also 
25 observed in different fractions of iodixanol gradient-separated HCVcc (Fig. 6C-F) in line with 
26 the higher infectivity and ApoE concentrations of HCVcc generated in OGT-silenced 
27 Huh7.5.1 cells (Fig. 5A-C). These data suggest that OGT-silencing affects the lipidation of 
28 HCVcc.
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1 OGT expression increases in liver disease. Since silencing of OGT promotes HCV 
2 infectivity, we assessed whether HCV infection in turn had an effect on miR-501-3p and OGT 
3 expression. In Huh7.5.1 cells, HCV infection lead to small but significant increase of miR-
4 501-3p and decrease of OGT levels (Fig. 7A-B and Supplementary Fig. 1B; p-value < 0.05, 
5 Mann-Whitney test), which may promote viral infection given the pro- and antiviral roles of 
6 miR-501-3p and O-GlcNAcylation, respectively (Fig. 1C-D and 4D). In contrast, no significant 
7 difference of OGT expression was observed between the livers of HCV transgenic and wild-
8 type mice[37] (data not shown) suggesting that HCV proteins do not directly modulate OGT 
9 expression. In liver tissue from HCV-infected patients, HCV RNA levels were not correlated 
10 with OGT expression (Fig. 7C, Spearman correlation: 0.06004019, p-value = 0.7661) 
11 suggesting that in patients there is likely no direct effect of HCV on OGT expression. 
12 O-GlcNAcylation has been associated with a variety of cancers, including HCC 
13 recurrence linked to increased O-GlcNAcylation after liver transplantation[38]. We therefore 
14 investigated OGT expression in chronic liver disease and HCC. While there was a trend for 
15 increased OGT expression in liver tissue from HCV-infected patients with fibrosis and 
16 inflammation (Fig. 7D-E), OGT levels were markedly and significantly elevated in the tumor 
17 liver tissue of patients chronically infected with HCV or hepatitis B virus and patients with 
18 alcoholic liver disease or non-alcoholic fatty liver disease as compared to non-tumor tissue 
19 (Fig. 7F, p-value < 0.05, Wilcoxon test). These data suggest that OGT expression increases 
20 in HCC in an etiology-independent manner. Collectively, these results suggest that OGT 
21 expression is likely increased in HCV-induced liver disease and cancer through inflammation 
22 and fibrosis rather than by HCV itself. 
23
24
25 Discussion
26 By focusing on miRNAs affecting late steps of the viral life cycle, we uncovered that i) miR-
27 501-3p regulates the expression of OGT; ii) silencing of OGT expression or inhibition of its 
28 enzymatic activity increases the infectivity of HCV particles; and iii) OGT knock-down leads 
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14
1 to the release of bigger HCV particles. Our data suggest that O-GlcNAcylation affects HCV 
2 morphogenesis and infectivity. 
3 While we were characterizing the role of OGT/O-GlcNAcylation for HCV 
4 morphogenesis, Li and colleagues published their functional genomics study of HCV-miRNA 
5 interactions[2]. By conducting genome wide miRNA mimic and hairpin inhibitor screens, they 
6 identified a set of miRNAs exhibiting a pro- or antiviral effect on HCV. Characterization of the 
7 underlying molecular processes showed that miR-25, let-7 and miR-130 families restrict viral 
8 infection by decreasing the expression of cellular HCV co-factors[2]. Despite similarities in 
9 the cell type and HCV infection models used here and by Li and colleagues, our screen only 
10 displays a small overlap with their study (9% common miRNA hits). This is not surprising 
11 given the small overlap between previous siRNA screens to uncover HCV host factors[8, 15] 
12 and is likely due i) to the different sizes of miRNA mimic libraries as the library used here was 
13 more than 2-times larger than the one used by Li and co-workers, and ii) to the markedly 
14 distinct pipelines for hit selection that were used in the two studies. Nonetheless, both 
15 screens were consistent in confirming the proviral role of miR-146a-5p in promoting HCV 
16 assembly/egress that we previously reported[17] and the global multistep inhibitory effects of 
17 the let-7 family on HCV infection[28], further corroborating the involvement of these miRNAs 
18 in fine-tuning the HCV life cycle. Both studies also consistently indicated that miR-518a-5p, 
19 miR-517-3p, miR-185 and members of the miR-302 family inhibit early steps of HCV 
20 infection, while miR-586, miR-620 and members of the miR-200 family inhibit late steps of 
21 viral infection. Since none of these miRNAs except miR-185 has been previously associated 
22 with HCV infection[39], it might be interesting to further characterize the involvement of these 
23 miRNAs in HCV-host interactions. Interestingly, an overall proviral effect of miR-501-3p was 
24 also observed by Li and colleagues[2], however the mechanism of action was not studied. By 
25 characterizing the role of miR-501-3p in the HCV life cycle, we uncovered OGT as a miR-
26 501-3p target in liver-derived cells and showed for the first time a link between O-
27 GlcNAcylation and HCV infection. These results indicate that genome-wide miRNA functional 
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15
1 screens represent a powerful strategy to dissect the role of miRNAs in pathogen-host 
2 interactions. 
3 While N-glycosylation of HCV envelope glycoproteins plays an important role for 
4 escape from virus-neutralizing antibodies[40], so far no functional association between HCV 
5 and O-glycosylation has been reported. In contrast to N-linked glycosylation that consists of 
6 the attachment of a glycan to a nitrogen of an asparagine residue of proteins in the ER/Golgi 
7 prior to their trafficking to the plasma membrane and/or their secretion, the glycosylation of 
8 serine and threonine residues with O-GlcNAc is a post-translational modification (PTM) of 
9 intracellular proteins that are localized in the nucleus, cytoplasm or mitochondria. The O-
10 glycosylation/deglycosylatio  of proteins is catalyzed by a single pair of nucleo-cytoplasmic 
11 enzymes, OGT/OGA. O-GlcNAcylation is complementary to protein 
12 phosphorylation/dephosphorylation, another more broadly known abundant protein PTM that 
13 involves numerous kinases/phosphatases. OGT/OGA are often found in protein complexes 
14 that also include kinases/phosphatases and a protein can be either O-GlcNAcylated or 
15 phosphorylated on a same residue to fine-tune cellular signaling[41]. O-GlcNAcylation and 
16 phosphorylation on the same or neighboring serine or threonine residue is known as yin yang 
17 site[42]. 
18 O-GlcNAcylation plays a major role in the regulation of metabolic pathways in the 
19 liver, including insulin signaling, bile acid metabolism and lipogenesis[35]. The large number 
20 of OGT/OGA substrates and cellular pathways regulated by O-GlcNAcylation hampers a 
21 detailed characterization of the role of these proteins in HCV infection. Since i) HCV 
22 assembly takes place at ER-derived membranes, ii) OGT/OGA are not known to localize in 
23 the ER lumen, and iii) O-GlcNAcylation of extracellular proteins containing EGF-like domains 
24 is catalyzed by EGF domain-specific OGT (EOGT) in the ER lumen in an OGT-independent 
25 manner[43]), OGT/OGA most likely modulate HCV infection by post-translationally modifying 
26 one or several cellular factors required for HCV morphogenesis rather than by affecting viral 
27 proteins, although HCV glycoproteins contain putative O-GlcNAcylation sites as determined 
28 using OGlcNAcScan, OGTsite and YingOYang1.2 bioinformatics tools (data not shown). 
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16
1 Regarding HCV host factors that may be regulated by OGT/OGA, O-GlcNAcylation 
2 sites have been predicted in human CLDN1[44] and OCLN at serine sites that can also be 
3 phosphorylated and this has been suggested to potentially play a role for HCV entry[45]. 
4 However, in our experimental setting we did not observe a significant effect of OGT-silencing 
5 on the early steps of HCV infection, suggesting that O-GlcNAcylation of CLDN1 and/or 
6 OCLN likely does not play a major role in HCV infection. Other host factors important for the 
7 HCV life cycle are well-known O-GlcNAcylated proteins, as for example various nuclear pore 
8 complex proteins (Nups) including Nup98, Nup153 and Nup155 that are involved in HCV 
9 replication and assembly and/or may be associated with viral particles[46, 47, 48]. However, 
10 since depletion of Nups was reported to alter HCV replication and/or assembly but to have 
11 no impact on the specific infectivity of HCV particles[46] in contrast to the depletion of OGT 
12 as shown here, it is unlikely that a modulation of Nup O-GlcNAcylation accounts for the 
13 effects of OGT-silencing and/or OGT/OGA inhibitors on HCVcc infectivity observed in our 
14 study. This is in line with our observation that OGT knock-down had no effect on Dengue 
15 virus (DENV) replication and infectivity (unpublished observations KH, MZ and Evelyne 
16 Schaffer, IBMC, Strasbourg), although Nup98 had been suggested to potentially play a role 
17 for DENV infection[46]. These data suggest that OGT does not broadly modulate the 
18 infectivity of viruses of the Flaviviridae family. 
19 However, OGT and/or O-GlcNAcylation have been reported to play a role in the 
20 infection with other viruses[49, 50, 51]. Interestingly, while OGT expression modulates the 
21 levels of human papillomavirus 16 (HPV16) oncoproteins E6 and E7[52], E6 in turn can up-
22 regulate OGT to increase O-GlcNAcylation and the oncogene activities of HPV[53], 
23 suggesting that OGT/O-GlcNAcylation could play a role in virus-induced cancer. In cell 
24 culture, HCV infection appeared to be associated with a minor decrease in OGT expression 
25 in line with an antiviral role of O-GlcNAcylation. In contrast, an increased OGT expression 
26 was observed in HCC tissues of HCV-infected patients. Since OGT has been suggested to 
27 activate oncogenic signaling pathways in non-alcoholic steatohepatitis-related HCC[54] and 
28 O-GlcNAcylation has been associated with HCC recurrence linked to increased O-
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17
1 GlcNAcylation after liver transplantation[38], these data suggest that in addition to their effect 
2 on the HCV life cycle, OGT/O-GlcNAcylation may also play a role in HCV-induced 
3 hepatocarcinogenesis.
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1 Figure legends
2 Figure 1. High-throughput screen identifies human miRNAs that regulate the HCV life 
3 cycle. (A) Schematic outline of the miRNA mimic screen strategy. Huh7.5.1 cells were 
4 transfected with miRNA mimics or controls prior to infection with Renilla luciferase HCVcc 
5 (JcR2a) two days later (part 1). Cell supernatants of part 1 were used to inoculate naïve 
6 Huh7.5.1 cells (part 2). Cells from part 1 and part 2 were lysed at the end of each infection 
7 step (2 and 3 days post infection, respectively) to determine luciferase activity. (B) 
8 Modulation of HCV entry and replication (part 1) and/or assembly and infectivity (part 2) upon 
9 transfection of control non-targeting siRNA (siCtrl, negative control), siCD81 (inhibiting viral 
10 entry) or siApoE (inhibiting viral assembly). By inhibiting HCV entry, siCD81 impacts part 1 
11 as well as part 2. In contrast, by specifically impairing late steps of HCV replication cycle, 
12 siApoE inhibits HCV infection only in part 2. The box plots show the sample lower quartile 
13 (25th percentile; bottom of the box), the median (50th percentile; horizontal line in box) and 
14 the upper quartile (75th percentile; top of the box) of relative light units (RLU) in each lysate. 
15 The whiskers indicate s.d. Data are from three independent experiments. (C) Effects of 
16 miRNA overexpression on each part of the HCV life cycle. Data were tested using a 
17 moderated t-test (empirical Bayes shrinkage, R-package limma[26]) for the null-hypothesis of 
18 no change of a given miRNA compared to the negative control. The resulting p-values for 
19 independent testing of each miRNA where corrected for the multiple testing situation and 
20 expressed as local false discovery rate (lfdr, R-package fdrtool[27]). miRNAs having a 
21 significant effect on either part 1 or 2 of the screen are below the thresholds indicated by 
22 dashed lines (lfdr < 0.00027 or 0.1226, respectively). miRNAs that were previously reported 
23 to impact on HCV infection as well as miR-140-3p, miR-501-3p, miR-619-3p and miR-4778-
24 5p are highlighted in blue (Log2(FC) < 0) or red (Log2(FC) > 0). Data are from three 
25 independent experiments. (D) Effect of miR-140-3p, miR-501-3p, miR-619-3p and miR-4778-
26 5p on the HCV life cycle. Huh7.5.1 cells were transfected with siCtrl (Ctrl), miR-140-3p, miR-
27 501-3p, miR-619-3p or miR-4778-5p and infection experiments were carried out as described 
28 in A. HCV infection was determined as luciferase activity. Results represent mean 
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24
1 percentage ± s.d. from three independent experiments in triplicate. The dashed line indicates 
2 values from control-transfected cells set at 100%. Statistics: *, p-value < 0.05, Mann-Whitney 
3 test.
4
5 Figure 2. OGT is a novel host cell factor involved in the late steps of the HCV life cycle. 
6 Huh7.5.1 cells were transfected with a set of siRNAs against 28 predicted targets of miR-
7 501-3p and/or miR-619-3p, and infected with HCVcc JcR2A according to the two-step 
8 protocol depicted in Fig. 1A. siCD81, antagomiR-122 and siApoE were used as loss-of-
9 function controls to perturb HCV entry, translation/replication and assembly, respectively. 
10 miR-501-3p and miR-619-3p, which were ineffective in part 1 of the screen but enhanced 
11 HCV infection in part 2, were transfected in parallel. HCV infection was quantified as fold 
12 change of luciferase activity with respect to negative control (siCtrl). Results for different 
13 replicates are shown as individual points. For each gene, median fold change of luciferase 
14 activity ± s.d. is shown as black horizontal lines. The dashed line indicates a fold change of 
15 1. Data are from three independent experiments in triplicate. Results for miR-501-3p, miR-
16 619-3p and siOGT that increase HCV infection in part 2 are depicted in red. Results for 
17 siRNA targeting PPP3CA, CEBPA, MID1, WDFY3, DCX, SLC35D1, CSDE1, GAN, USP37, 
18 MAPK9, DCC, RNF144A, or PPP2R2C that significantly modulated HCV infection in part 1 
19 and/or part 2 but did not phenocopy the effect of miR-501-3p and miR-619-3p are depicted in 
20 blue.
21
22 Figure 3. miR-501-3p mediates post-transcriptional regulation of OGT by decreasing 
23 its expression at the protein level. Huh7.5.1 cells were transfected with siCtrl (Ctrl), a pool 
24 of siRNA against OGT, miR-501-3p or miR-619-3p. After 96h, RNA and proteins were 
25 purified, and OGT expression analyzed by RT-qPCR and Western blot. (A) Percentage of 
26 OGT mRNA expression in miRNA-transfected cells as compared to negative control. Results 
27 are presented as mean ± s.d. and are from three independent experiments in triplicate. The 
28 dashed line indicates values from control-transfected cells set at 100%. Statistics: *, p-value 
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25
1 < 0.05, t-test (B) OGT protein expression. Left: percentage of OGT protein expression in 
2 siRNA- or miRNA-transfected cells as assessed by quantification of Western blots. OGT 
3 levels were normalized to actin levels using ImageLab™ 5.2.1 software (BioRad). Results 
4 are presented as mean ± s.d. and are from three independent experiments. The dashed line 
5 indicates values from control-transfected cells set at 100%. Statistics: *, p-value < 0.05, t-
6 test. Right: representative Western blot analysis. (C) Analysis of miRNA targeting of OGT 
7 expression by dual luciferase reporter assay. Left: HeLa cells were co-transfected with a 
8 miR-501-3p mimic and a dual luciferase reporter plasmid containing either wild type miR-
9 501-3p (RLuc wt OGT 3’UTR) or mutated miR-501-3p binding site (RLuc mt OGT 3’UTR) to 
10 modulate RLuc expression. Co-transfection of the miR-501-3p mimic and empty RLuc vector 
11 was used as control. Data are expressed as mean percentage of Renilla luciferase activity ± 
12 s.d. normalized to firefly luciferase, and relative to co-transfection of the vectors with non-
13 targeting miRNA (miR-Ctrl). Results are from three independent experiments in triplicate. 
14 The dashed line indicates values from control-transfected cells set at 100%. Statistics: *, p-
15 value < 0.05, t-test. Right: Schematic representation of the used constructs. 
16
17 Figure 4. Silencing of OGT affects HCV morphogenesis and infectivity. (A) Analysis of 
18 HCV infectivity. Huh7.5.1 cells were transfected with siCtrl, a pool of siRNA against OGT or 
19 ApoE as a loss-of-function control to perturb HCV assembly, prior to infection with HCVcc 
20 (Jc1) two days later (entry and replication). Mock-transfected cells were used as control 
21 (Ctrl). After another 48h, intra- and extracellular HCVcc particles were used to infect naïve 
22 Huh7.5.1 cells (assembly and infectivity). Virus supernatants of Huh7.5.1 cells were assayed 
23 by (left) endpoint dilution assay (TCID50). Intra- and extracellular HCV RNA was purified and 
24 analyzed by RT-qPCR to calculate (right) the specific infectivity (TCID50/RNA). Data are 
25 expressed as mean percentage as compared to control ± s.d. Results are from four 
26 independent experiments in triplicate. The dashed line indicates values from control-
27 transfected cells set at 100%. Statistics: *, p-value < 0.05, Mann-Whitney test. (B) Genotype-
28 independent effect of OGT on HCV infection. Huh7.5.1 cells were transfected with siCtrl or 
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1 siOGT prior to infection with HCVcc JcR2a (genotype 2a), H77R2a (genotype 1a) or 
2 Con1R2a (genotype 1b). Experiments were carried out and analyzed as described in A. Data 
3 are expressed as mean percentage of Renilla luciferase activity as compared to control ± s.d. 
4 Results are from three independent experiments in quadruplicate. The dashed line indicates 
5 values from control-transfected cells set at 100%. Statistics: *, p-value < 0.05, Mann-Whitney 
6 test. (C) Activity of OGT/OGA inhibitors on O-GlcNAcylation. The activity of Ac45S-GlcNAc 
7 (OGT inhibitor) or Thiamet G (OGA inhibitor) on O-GlcNAcylation of proteins in Huh7.5.1 
8 cells was demonstrated by Western blot as described in Supplementary Methods. (D) Effect 
9 of O-GlcNAcylation on HCV infectivity. Huh7.5.1 cells were electroporated with HCVcc 
10 (JcR2a), prior to treatment with increasing concentrations of Ac45S-GlcNAc (OGT inhibitor, 
11 left) or Thiamet G (OGA inhibitor, right) 4h later. After 96h, supernatants were transferred 
12 onto naïve Huh7.5.1 cells and electroporated cells were lysed to determine luciferase 
13 activity. Luciferase activity in infected Huh7.5.1 cells was assessed 72h later. Data are 
14 expressed as mean percentage as compared to control ± s.d. Results are from three 
15 independent experiments in quadruplicate. The dashed line indicates values from vehicle-
16 treated cells set at 100%. Statistics: *, p-value < 0.05, Mann-Whitney test. 
17
18 Figure 5. Silencing of OGT modulates HCVcc biophysical properties. (A) Separation of 
19 HCVcc by iodixanol density gradient ultracentrifugation. HCVcc were produced in non-
20 targeting siRNA control- or siOGT-transfected Huh7.5.1 cells. After overlaying HCVcc 
21 (JcR2A) on a 4%-40% iodixanol step gradient and ultracentrifugation for 16h, fractions of 
22 HCV particles were used to infect naïve Huh7.5.1 cells in order to determine TCID50. HCV 
23 RNA of each fraction was purified and analyzed by RT-qPCR. Data are expressed as mean ± 
24 s.d. from three independent experiments. (B) Specific infectivity (TCID50/RNA) was 
25 calculated and the density was determined by weighting each fraction. Specific infectivity of 
26 each fraction is expressed as fold change as compared to the total infectivity of the control. 
27 Data are expressed as mean ± s.d. from three independent experiments. (C-D) ApoE and 
28 ApoB concentrations in the individual fractions were determined by ELISA. The dashed lines 
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27
1 indicate limits of quantification of the assays. Data are expressed as mean ± s.d. from three 
2 independent experiments. 
3
4 Figure 6. Silencing of OGT increases the size of HCVcc. (A) Representative pictures of 
5 HCV particles generated in Huh7.5.1 cells transfected with non-targeting siRNA (siCtrl) or 
6 siOGT. (B-F) Comparative analysis of particle size distribution for immunocapture (IC) from 
7 HCV particles produced in Huh7.5.1 cells transfected with siCtrl or siOGT prior to infection 
8 with HCVcc (JcR2a) following sucrose-cushion purification (B) or iodixanol gradient 
9 fractionation (C-F) of HCVcc. HCVcc were transferred via anti-E2 antibody AR3A on electron 
10 microscopy (EM) grids through IC. Particle size distribution was assessed from a series of 
11 randomly acquired electron micrographs with Image-J software (NIH). Results from one of 
12 three (A-B) or two (C-F) independent experiments are shown. Black lines: size distribution of 
13 immunocaptured HCVcc produced in siCtrl-transfected cells. Grey lines: size distribution of 
14 immunocaptured HCVcc produced in siOGT-transfected cells. 
15
16 Figure 7. OGT expression increases in HCC. (A-B) Huh7.5.1 cells were infected with HCV 
17 (JcR2a). After 72h, RNA and proteins were purified, and OGT expression analyzed by RT-
18 qPCR and Western blot. (A) Percentage of OGT mRNA expression relative to uninfected 
19 Huh7.5.1 cells (Ctrl). Results are presented as mean ± s.d. from three independent 
20 experiments in duplicate. The dashed line indicates values from uninfected Huh7.5.1 cells 
21 set at 100%. Statistics: *, p-value < 0.05, Mann-Whitney test. (B) OGT protein expression. 
22 Left: percentage of OGT protein expression relative to uninfected Huh7.5.1 cells (Ctrl) 
23 following quantification of Western blots as described in Supplementary Methods. Results 
24 are presented as mean ± s.d. from three independent experiments. The dashed line 
25 indicates values from uninfected Huh7.5.1 cells set at 100%. Statistics: *, p-value < 0.05, 
26 Mann-Whitney test. Right: representative Western blot analysis of OGT and actin. (C) OGT 
27 expression and viral load in liver tissue from 22 HCV-infected patients and 6 patients not 
28 infected with HCV described in[55]. Spearman correlation: rho = 0.06004019, p-value = 0.77. 
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28
1 (D-E) OGT expression in liver tissue from 22 HCV-infected patients and 6 patients not 
2 infected with HCV according to fibrosis (D) or activity (E) scores described in[55]. Wilcoxon 
3 test: F1 vs F0 p-value = 0,38; F2 vs F0 p-value = 0,18; F3 vs F0 p-value = 0,43; F4 vs F0 p-
4 value = 0,17; A1 vs A0 p-value = 0,28; A2 vs A0 p-value = 0,23; A3 vs A0 p-value = 0,09. (F) 
5 OGT expression in tumor (HCC) and non-tumor (Ctrl) liver tissue from 39 HCV-infected 
6 patients, 83 HBV-infected, 80 patients with alcoholic liver disease (ALD) and 13 patients with 
7 non-alcoholic liver disease (NAFLD) as described in Supplementary Methods. *, p-value < 
8 0.05, Wilcoxon test.
9
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29
1 Table 1. Computational analysis of miR-501-3p and miR-619-3p targets and pathway 
2 enrichment. 
miRNA ID Target gene symbol Pathway or network
miR-501-3p MEF2A; PPP3CA; PPP3CC Calcium signaling
HMGCS1 Cholesterol biosynthesis
AFF4; CHMP1B; CUX1; DCLK1; 
LMX1A; PTBP2; RBMS1; RC3H1; 
SCN2A; SEC63; ZFHX4
Inflammatory response, dermatological 
diseases and conditions, inflammatory 
disease
CDK6; CSDE1; GLI2; HOXD10; 
LSM5; MEF2A; MYCN; OGT; 
PPP2R2C; PPP2R5E; SEMA3C; 
TFDP2
Cellular development, nervous system 
development and function; organ 
morphology
CIT; COL10A1; FNBP1L; GAN; 
HERC1; KPNA4; NONO; SHPRH; 
STRN; TARDBP; UBE2H; USP37
Cell death and survival; cellular 
compromise; free radical scavenging
ATXN1; CBLL1; CEBPA; DCC; 
PEX5L; RCC2; RNF144A; ZC3H12C
Cell morphology, cellular assembly and 
organization; cellular function and 
maintenance
miR-619-3p RUNX1T1; SMAD3 Adipocyte biogenesis
FOXG1; GPBP1; MID1; MKL2; MSI1; 
PCBP2; WDFY3
Cell cycle; organismal injury and 
abnormalities; cancer
ACVR2B; DCX; ESRRG; MAPK9; 
OGT; PCBP1; PDE3B; SMAD3; 
SMARCC1; TGFB3; PAPOLA
Carbohydrate metabolism, energy 
production; small molecule biochemistry
RUNX1T1; SHANK2; SLC35D1 Gene expression, lipid metabolism, small 
molecule biochemistry
3
4
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23 Supplementary Material and methods
24 Cells and cell culture conditions. The source and culture conditions of Huh7.5.1 cells have 
25 been described[1]. HeLa cells were purchased from ATCC and cultured in Dulbecco´s 
26 modified Eagle medium (Gibco® DMEM GlutaMAX™, ThermoFisher Scientific) containing 1% 
27 sodium pyruvate as described for Huh7.5.1 cells[1]. 
Page 79 of 84
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
2
1 Viruses and infectivity assays. Cell culture-derived recombinant cell culture-derived 
2 hepatitis C virus (HCVcc) Jc1 (genotype 2a/2a chimera), H77R2a (genotype 1a/2a chimera 
3 engineered for Renilla luciferase expression), Con1R2a (genotype 1b/2b chimera engineered 
4 for Renilla luciferase expression), and JcR2a (genotype 2a/2a chimera engineered for Renilla 
5 luciferase expression) were generated in Huh7.5.1 cells as described[1, 2, 3, 4]. HCVcc 
6 infectivity was determined by calculating the 50% tissue culture infectious dose (TCID50) 
7 using anti-NS5A antibody as described[5, 6] or by assessing luciferase activity. HCVcc were 
8 used at 105-106 TCID50/mL throughout the study. HCV RNA was purified using a QIAmp viral 
9 RNA minikit (Qiagen) and analyzed by one-step RT-qPCR using a Sensi Fast NO ROX kit 
10 (Bioline) according to the manufacturer’s instructions. Standard curves were performed using 
11 10-fold dilution series of HCV RNA.
12
13 Purification of HCVcc particles using sucrose cushion or iodixanol density gradient. 
14 HCVcc (JcR2a) were concentrated 10-fold using a Vivaspin column (GE Healthcare). For 
15 sucrose cushion purification, HCVcc were purified by overlaying 3.5 mL of culture media on 
16 1.5 mL of 20% sucrose, and by ultracentrifuging samples for 4h at 40,000 rpm on a SW-55 
17 rotor (Beckman Coulter). Purified HCVcc were resuspended in 30 µL of PBS for analysis via 
18 immunocapture and electron microscopy. Density distributions of infectious HCVcc were 
19 determined by overlaying 0.5 mL culture media on a 5 mL, 4%-40% iodixanol step gradient, 
20 and ultracentrifuging samples for 16h at 40,000 rpm on a SW-55 rotor (Beckman Coulter): 625 
21 µl fractions were carefully harvested from the top of each tube, and density was determined 
22 by weighing. Infectivity of each fraction was quantified by TCID50 using anti-NS5A antibody 
23 as described[5, 6], while HCV RNA of fractions was purified and analyzed as described above. 
24 ApoB and ApoE concentrations of fractions were determined by enzyme-linked 
25 immunosorbent assay (Human Apolipoprotein B or E ELISAPRO kit, Mabtech) undiluted or in a 
26 1:50 dilution, respectively, according to the manufacturer’s instructions (Mabtech). 
27
Page 80 of 84
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
3
1 miRNA mimics and siRNAs. Non-targeting control miRNA, miR-501-3p mimic, miR-619-3p 
2 mimic, antagomiR-122, antagomiR-501-3p, non-targeting control antagomiR, non-targeting 
3 control siRNA, siRNAs targeting OGT, CD81 or apoliporotein E (ApoE) and a library of 28 
4 custom ON-TARGETplus smart pool siRNAs were purchased from Dharmacon (GE 
5 Healthcare).
6
7 miRNA expression analysis. Total RNA (100 ng) was purified from control or HCV-infected 
8 Huh7.5.1 cells using Tri reagent® (Thermo Scientific) and Direct-zol™ RNA purification kit 
9 (Zymo Research). Total RNA was first polyadenylated and reverse transcribed using a 
10 miScript II RT system (Qiagen) according to the manufacturer’s instructions. The obtained 
11 cDNA was subjected to RT-qPCR using miScript SYBR Green kit (Qiagen). Primers were the 
12 mature miRNA sequence for the forward primer (Thermo Scientific) and the universal miScript 
13 primer (Qiagen) for the reverse primer. Data were analyzed by the ΔΔCt method using small 
14 nucleolar RNA, C/D box 61 (SNORD61) as an endogenous reference and the non-infected 
15 samples as a calibrator[7].
16
17 Antibodies. Rabbit anti-OGT antibodies DM-17 and AL24 were purchased from Sigma or 
18 kindly provided by Dr. G. W. Hart and Dr. S. Hardivillé (Johns Hopkins University School of 
19 Medicine, Baltimore, MD)[8], respectively. Mouse anti--actin antibody was purchased from 
20 Abcam and mouse, rabbit or sheep HRP-conjugated secondary antibodies (A9044, A0545 
21 and A3415, respectively) were purchased from Sigma. Sheep anti-NS5A serum for 
22 determination of TCID50 was a kind gift from M. Harris[9]. Human anti-E2 (AR3A) antibody[10] 
23 for electron microscopy analysis was kindly provided by Mansun Law (SCRIPPS, California, 
24 USA). 
25
26 Western blotting. OGT and actin protein expression in human cells was assessed by 
27 Western blot as described[8] with some modifications. Briefly, cells were lysed in lysis buffer 
28 no. 6 (R&D Systems) according to the manufacturer's instructions. Equal amounts of protein 
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4
1 (40 µg) were size-separated through a Mini PROTEAN® TGX Stain-Free™ gel electrophoresis 
2 (Bio-Rad) and transferred to PVDF membranes (Bio-Rad). Immunoblots were performed 
3 using rabbit anti-OGT (1:2000) and mouse anti--actin (1:1000) antibodies[8, 11]. Antigen-
4 antibody complexes were detected by incubating the membrane with the appropriate HRP-
5 conjugated secondary antibodies (1:5000; 1:10,000) and imaged by enhanced 
6 chemiluminescence with a ChemiDoc MP imager (Bio-Rad). Quantification of protein 
7 expression was performed using ImageLab™ 5.2.1 software (BioRad). For analysis of OGT 
8 and GAPDH expression in liver tissue from HCV transgenic (FL-N/35) or wild-type mice[12], 
9 crude protein extracts were prepared by homogenization of frozen mouse livers (50–100 µg) 
10 in tissue lysis buffer from the Ambion PARIS RNA (Thermo Scientific) and protein isolation kit, 
11 supplemented with protease inhibitors (cOmpleteTM EDTA-free protease inhibitor mixture, 
12 Sigma-Aldrich) and phosphatase inhibitors (PhosSTOPTM, Sigma-Aldrich), using a tissue 
13 homogenizer (MP Fast Prep24, MP Biomedicals, Santa Ana, CA) and MP Lysing Matrix A 
14 tubes. Proteins were quantified using the BCA assay (Thermo Fisher Scientific). Western 
15 blotting was performed as described above.
16
17 Immunocapture and electron microscopy analysis of viral particles. Sucrose-cushion 
18 purified or iodixanol gradient fractionated HCVcc (JcR2a) produced in cells transfected with a 
19 non-targeting siRNA control or a pool of siRNA against OGT were transferred via anti-E2 
20 antibody AR3A on electron microscopy (EM) grids through immunocapture (IC) as 
21 described[13]. Particles were stained with uranyl acetate dihydrate and observed in a JEOL 
22 1230 electron microscope. Series of electron micrographs were acquired at random from IC 
23 EM grids. The images were then analyzed with Image-J software, to determine the particle 
24 size distribution.
25
26 Gene expression analysis in patient-derived liver tissue. For OGT expression analysis in 
27 patient’s samples, raw data were retrieved from the Gene Expression Omnibus (GSE84346) 
28 and re-analyzed by quality-trimming (cutadapt) and mapping (HISAT2) to human genome 
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19 Supplementary figure legends
20 Figure S1. (A) Effect of miR-501-3p inhibition on HCV infectivity. Huh7.5.1 cells were 
21 transfected with control antagomiR (Ctrl), antagomiR-122 as loss-of-function control to perturb 
22 HCV replication and antagomiR-501-3p, prior to infection with HCVcc (JcR2a) according to 
23 the two-step protocol depicted in Fig. 1A. After 48h, supernatants were transferred onto naive 
24 Huh7.5.1 cells. After 72h, Renilla Luciferase activity of infected Huh7.5.1 cells was 
25 determined. Data are expressed as mean percentage as compared to Ctrl ± s.d. Results are 
26 from four independent experiments in quadruplicate. The dashed line indicates values from 
27 vehicle-treated cells set at 100%. Statistics: *, p-value < 0.05, Mann-Whitney test. (B) miR-
28 501-3p expression upon HCV infection. Huh7.5.1 cells were infected with HCVcc (JcR2a). 
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7
1 After 72h, RNA was purified and miR-501-3p expression analyzed by RT-qPCR. Percentage 
2 of miR-501-3p expression relative to uninfected Huh7.5.1 cells (Ctrl). Results are presented 
3 as mean ± s.d. from three independent experiments in duplicate. The dashed line indicates 
4 values from uninfected Huh7.5.1 cells set at 100%. Statistics: *, p-value < 0.05, Mann-Whitney 
5 test.
6
7 Supplementary Table 1. A genome-wide miRNA mimic screen identifies cellular 
8 miRNAs modulating HCV infection. Log2(FC), lfdr and effect on HCV infection in part 1 and 
9 part 2 of the screen are shown for the individual miRNAs of the miRNA mimic library. In red: 
10 proviral effect, in blue: antiviral effect. FC: fold change, lfdr: local false discovery rate
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